使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to the Align Q1 '21 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Shirley Stacy, Vice President, Corporate Communications and Investor Relations. Please go ahead.
各位好,歡迎參加 Align 2021 年第一季(Q1 '21)財報電話會議。(接線員指示)提醒各位,本次會議將被錄音。現在我想把會議交給今天的主持人——企業傳播與投資人關係副總裁 Shirley Stacy。請開始。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.
各位下午好,感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有:總裁暨執行長 Joe Hogan,以及財務長 John Morici。
We issued first quarter 2021 financial results today via Globe Newswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on May 12. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13718065 followed by pound. International callers should dial (201) 612-7415 with the same conference number.
我們今日已透過 Globe Newswire 發布 2021 年第一季財務結果,並可於我們網站 investor.aligntech.com 取得。今天的電話會議將以音訊網路直播,並將在我們網站上保存約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,並持續至 5 月 12 日美東時間下午 5:30。欲收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13718065 後按井字鍵。國際來電者請撥打 (201) 612-7415,並輸入相同的會議編號。
As a reminder, the information provided and discussed today will include forward-looking statements including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission, available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天所提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會(SEC)提交的定期報告中有更詳細的說明,可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We have posted historical financial statements, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our first quarter 2021 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information. Please note, as of Q1 '21, we are no longer including number of doctors trained, Clear Aligner shipment volume by region and total worldwide average selling price. We will continue to share information management uses to evaluate the business and metrics to help investors and analysts assess our financial performance.
我們已在網站「季度業績(Quarterly Results)」專區發布歷史財務報表(含相應調節表),包括(如適用)GAAP 與非 GAAP 的調節,以及 2021 年第一季電話會議簡報。請參閱這些檔案以取得更詳細資訊。請注意,自 2021 年第一季起,我們不再提供受訓醫師人數、依地區區分的透明矯正器出貨量,以及全球平均銷售價格總計。我們將持續分享管理層用以評估業務的資訊,以及協助投資人與分析師評估我們財務表現的指標。
With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights from the first quarter, then briefly discuss the performance of our 2 operating segments, Clear Aligners and Systems and Services. John will provide more detail on our financial results and discuss our outlook for the full year. Following that, I'll come back and summarize a few key points and open the call to questions.
謝謝你,Shirley。各位下午好,感謝各位加入。今天的電話會議中,我將先提供第一季的一些重點摘要,接著簡要說明我們兩個營運部門——透明矯正器(Clear Aligners)以及系統與服務(Systems and Services)的表現。John 將更詳細說明我們的財務結果,並討論全年展望。之後我會回來總結幾個關鍵重點,並開放提問。
I'm pleased to report another strong quarter with record revenues and volumes reflecting strong growth for both Invisalign Clear Aligners and iTero Systems and Services across products and customer channels worldwide. Q1 sequential Invisalign Clear Aligner growth was driven by strength in both adult and teen market segments across products, customer channels, especially in North America and the EMEA region. The year is off to a great start, and Q1 reflects increasing momentum and the benefit from continued investments in our strategic initiatives focusing on: expanding our operations globally in existing and emerging international markets; increasing ortho adoption and utilization of Invisalign treatment, especially with teens; training and education GP dentists; an increasing conversion to Clear Aligners; and building Invisalign brand preference with millions of consumers through advertising, PR, digital, social media and influencer marketing to drive demand and conversion through Invisalign-trained doctors.
我很高興報告,我們再度交出強勁的一季,營收與出貨量皆創新高,反映 Invisalign 透明矯正器與 iTero 系統與服務在全球各產品與客戶通路的強勁成長。第一季 Invisalign 透明矯正器的季增成長,主要來自成人與青少年兩大市場區隔在各產品與客戶通路的強勢表現,尤其是在北美與 EMEA 地區。今年開局非常良好,第一季展現了動能提升,以及我們持續投資策略性計畫所帶來的效益,重點包括:在既有與新興國際市場擴大全球營運;提升矯正科對 Invisalign 治療的採用與使用率,特別是在青少年族群;對一般牙醫(GP)進行訓練與教育;加速向透明矯正器的轉換;並透過廣告、公關、數位、社群媒體與網紅行銷,向數以百萬計的消費者建立 Invisalign 品牌偏好,以帶動需求並透過受訓的 Invisalign 醫師促成轉換。
For Q1, total revenues were $894.8 million, up 7.2% sequentially and 62.4% year-over-year. Q1 System and Services were $141.5 million, up 5.8% sequentially and up 104% year-over-year. Q1 '21 Clear Aligner revenues of $753.3 million were up 7.5% sequentially and increased of 56.4% year-over-year.
第一季總營收為 8.948 億美元,季增 7.2%,年增 62.4%。第一季系統與服務營收為 1.415 億美元,季增 5.8%,年增 104%。2021 年第一季透明矯正器營收為 7.533 億美元,季增 7.5%,年增 56.4%。
In Q1, we shipped a record 595,800 Invisalign cases, an increase of 4.9% sequentially and 65.8% year-over-year. In addition, we shipped to a record 78,600 Invisalign doctors worldwide, of which approximately 6,600 were first-time customers.
第一季我們出貨創紀錄的 595,800 件 Invisalign 病例(cases),季增 4.9%,年增 65.8%。此外,我們向全球創紀錄的 78,600 位 Invisalign 醫師出貨,其中約 6,600 位為首次下單的客戶。
During the quarter, we reached a significant milestone with our 10 millionth Invisalign patient, Gabriela Silva, who recently began our treatment with Dr. Eunice Blind, an Invisalign-trained orthodontist in São Paulo, Brazil, one of our fastest-growing country markets. It's remarkable to think about the pace of growth and adoption that we are experiencing worldwide, especially when considering it took 10 years to achieve our 1 millionth Invisalign patient milestone and now we're adding 1 million new Invisalign patients in less than 6 months. We're grateful to our doctor partners and their patients and to our 20,000 employees around the world who have helped us reach this milestone.
本季我們達成一項重要里程碑:第 1,000 萬位 Invisalign 病患——Gabriela Silva。她近期在巴西聖保羅由受訓的 Invisalign 矯正專科醫師 Dr. Eunice Blind 開始接受治療;巴西也是我們成長最快的國家市場之一。回顧我們在全球所經歷的成長與採用速度令人驚嘆,尤其是考量到我們花了 10 年才達成第 100 萬位 Invisalign 病患的里程碑,而現在我們在不到 6 個月內就新增 100 萬位 Invisalign 病患。我們感謝合作的醫師夥伴及其病患,也感謝全球 20,000 名員工協助我們達成此里程碑。
In recognition of our 10 millionth Invisalign milestone, we have donated $10 million to the Align Foundation donor-advised fund, are kicking off a campaign called 10 Million Smiles, 10 Million Thanks centered around the transformative power of Invisalign treatment through the eyes of Invisalign patients.
為紀念第 1,000 萬位 Invisalign 的里程碑,我們已向 Align Foundation 的捐贈者建議基金(donor-advised fund)捐贈 1,000 萬美元,並啟動名為「10 Million Smiles, 10 Million Thanks」的活動,透過 Invisalign 病患的視角,聚焦 Invisalign 治療所帶來的轉變力量。
From a product perspective, Q1 clear aligner revenues reflect strong growth across the Invisalign portfolio for both comprehensive and noncomprehensive products. Q1 comp volume increased 4.9% sequentially and 62.3% year-over-year, and Q1 non-comp or noncomprehensive volume increased 5.0% sequentially and 74.4% year-over-year. Invisalign Clear Aligners address a wide range of case complexity and can treat approximately 90% of case starts for adults and teens and phase 1 treatment for kids as young as 6 years old. Q1 adult patients increased 5.8% sequentially and 68.5% year-over-year. Q1 teens or younger patients increased 2.7% sequentially, 58.9% year-over-year. Teenage cases made up nearly 75% of the 15 million ortho starts each year and despite our rapid growth and adoption, Invisalign treatment is still only single digits worldwide, so we continue to see significant runway here.
從產品角度來看,第一季透明矯正器營收反映 Invisalign 產品組合在完整療程(comprehensive)與非完整療程(noncomprehensive)產品上的強勁成長。第一季完整療程出貨量季增 4.9%,年增 62.3%;第一季非完整療程出貨量季增 5.0%,年增 74.4%。Invisalign 透明矯正器可涵蓋廣泛的病例複雜度,約可治療成人與青少年約 90% 的起始病例(case starts),並可為最小 6 歲的兒童提供第一期(phase 1)治療。第一季成人病患數季增 5.8%,年增 68.5%。第一季青少年或更年幼病患數季增 2.7%,年增 58.9%。青少年病例幾乎占每年 1,500 萬件矯正起始病例的 75%;儘管我們成長與採用速度很快,Invisalign 治療在全球的滲透率仍僅為個位數,因此我們仍看到相當大的成長空間。
Our strong Q1 results also reflect our multimillion-dollar consumer marketing investment across key media channels with broad reach to drive consumers to Invisalign doctor practices. Our teen and mom-focused consumer campaign generated 138% year-over-year increase in unique visitors to our website and 35% increase in leads generated. In addition, Invisalign social media influencers like Charli D'Amelio, Avani Gregg, and Tan France and many other content creators/influencers enabled a delivery of 4.2 billion impressions in Q1 '21, delivering exciting new content and increased engagement for the Invisalign brand among their millions of followers.
我們第一季的強勁成果也反映了我們在關鍵媒體通路上投入數百萬美元的消費者行銷,以廣泛觸及受眾並引導消費者前往 Invisalign 醫師診所。我們以青少年與媽媽族群為主的消費者活動,使網站不重複訪客數年增 138%,並使所產生的潛在客戶(leads)增加 35%。此外,Invisalign 的社群媒體影響者(influencers),如 Charli D'Amelio、Avani Gregg、Tan France 以及許多其他內容創作者/影響者,在 2021 年第一季帶來 42 億次曝光(impressions),提供令人振奮的新內容,並在其數百萬追隨者之間提升 Invisalign 品牌互動。
The consumer insights and data we receive from our programs suggest adults are also continuing to invest more in themselves for their overall health and well-being and have more disposable income to do so. They are seeking Invisalign clear aligner treatment from our Invisalign doctors and sharing their positive experiences with their friends, family and social networks, becoming influencers themselves.
我們從各項計畫所獲得的消費者洞察與數據顯示,成人也持續在整體健康與福祉方面投入更多,且有更多可支配所得可用於此。他們正向我們的 Invisalign 醫師尋求 Invisalign 透明矯正器治療,並與朋友、家人及社群網路分享正面經驗,自己也成為影響者。
Now let's turn to the specifics around our first quarter results, starting with the Americas. For the Americas region, Q1 was another strong quarter with Invisalign case volume up 8.4% sequentially and 53.8% year-over-year reflecting increased Invisalign submitters and utilization growth for both orthodontic and GP channels. Q1 results also reflect continued investment in digital marketing, sales programs, our channel focus around GPs, orthos and DSOs and other initiatives to help drive utilization.
現在讓我們進入第一季業績的細節,先從美洲地區開始。就美洲地區而言,第一季再度表現強勁,Invisalign 病例量季增 8.4%,年增 53.8%,反映 Invisalign 提交者(submitters)增加,以及矯正專科與一般牙醫(GP)兩大通路的使用率成長。第一季結果亦反映我們持續投資於數位行銷、銷售方案、針對 GP、矯正專科(orthos)與牙科服務組織(DSOs)的通路聚焦,以及其他有助於推動使用率的計畫。
In the GP channel, Invisalign Moderate and Invisalign Go continue to gain traction. This was especially true for GP dentists that enrolled in the iPro program as well as doctors that have installed iTero scanners. The GP Accelerator program, designed exclusively for GPs, provides an all-encompassing support plan based on practice needs that is centered around maximizing iTero integration, clinical support needs and implementing new marketing strategies. DSO utilization also increased and continues to be a strong growth driver and outpaced non-DSO practices.
在 GP 通路方面,Invisalign Moderate 與 Invisalign Go 持續獲得市場動能。對於加入 iPro 計畫的 GP 牙醫,以及已安裝 iTero 掃描儀的醫師而言,這一趨勢尤其明顯。專為 GP 設計的 GP Accelerator 計畫,會依據診所需求提供全方位支援方案,核心在於最大化 iTero 整合、滿足臨床支援需求,並導入新的行銷策略。DSO 的使用率亦有所提升,並持續成為強勁的成長驅動力,且成長速度超越非 DSO 診所。
Today, we announced that we have extended our relationship with DECA Dental Group and have signed a new multiyear agreement for the Invisalign System through early 2025. In addition, DECA Dental Group is extending utilization of iTero Element 5D imaging system across its affiliate practices in the United States. This provides DECA Dental doctors and clinical support team members with access to Align's customized clinical education for the Invisalign system and the iTero Element 5D imaging system to support practices in adopting new workflows for restorative dentistry and for digital orthodontics.
今天,我們宣布已延長與 DECA Dental Group 的合作關係,並就 Invisalign 系統簽署一份新的多年期協議,合作期限延伸至 2025 年初。此外,DECA Dental Group 正在其美國的關聯診所擴大導入 iTero Element 5D 影像系統。此舉使 DECA Dental 的醫師與臨床支援團隊成員可取得 Align 為 Invisalign 系統與 iTero Element 5D 影像系統量身打造的臨床教育資源,以支援診所在修復牙科與數位矯正領域採用新的工作流程。
In the ortho channel, the Teen Awesomeness Centers program direct patients to Invisalign doctors who are experts are treating teens and are seen as the go-to doctors in their markets, helping to drive increased comprehensive treatments within the North American ortho channel. Tomorrow, registration opens for the 2021 Teen Forum: Virtual Edition to be held on June 10 and 11, which combines 2 days of all new dynamic sessions focused on the Invisalign teen patient journey. Sessions will focus on building clinical confidence, efficient workflows, teen and parent conversion and the overall digital treatment experience that teens expect. The timing of the forum is designed as a strong lead to the busy teen season, and attendees will have the option, at the post forum mentoring by Invisalign teen experts, to help orthos and their staff apply the tools from the teen forum to their practices and get additional support through their busy summer.
在矯正(ortho)通路方面,Teen Awesomeness Centers 計畫會將患者直接導向擅長青少年治療、並在其市場中被視為首選的 Invisalign 醫師,進而推動北美矯正通路中綜合性治療量的提升。明天將開放報名 2021 Teen Forum:Virtual Edition(虛擬版),活動將於 6 月 10 日與 11 日舉行,為期兩天,結合全新且具動態性的課程,聚焦於 Invisalign 青少年患者旅程。課程將著重於建立臨床信心、提升工作流程效率、青少年與家長的轉換,以及青少年所期待的整體數位治療體驗。論壇時程設計為繁忙的青少年旺季前的強力前導;與會者亦可選擇在論壇後接受 Invisalign 青少年專家提供的導師輔導,協助矯正醫師及其團隊將青少年論壇的工具應用於診所,並在忙碌的夏季期間獲得額外支援。
For our international business, Q1 Invisalign case volume was up sequentially 0.9%. On a year-over-year basis, international shipments were up 83.2%. In EMEA, Q1 volumes were sequentially 3.7%, up 74.9% year-over-year, with strong broad-based growth across all markets, led by the U.K., France and Italy, along with continued growth in our expansion markets, led by Turkey, Russia, CIS and Benelux. We also saw strong performance from both ortho and GP channels, with momentum in the GP channels with adults reflected in strong utilization in shipments from Invisalign Go.
就我們的國際業務而言,第一季 Invisalign 病例量較前一季增加 0.9%。以年對年來看,國際出貨量成長 83.2%。在 EMEA 地區,第一季量能較前一季增加 3.7%,年對年成長 74.9%,各市場皆呈現強勁且廣泛的成長,主要由英國、法國與義大利帶動,同時我們的擴張市場亦持續成長,主要由土耳其、俄羅斯、CIS 與 Benelux 帶動。我們也看到矯正與 GP 兩個通路皆表現強勁;在 GP 通路方面,成人動能反映在 Invisalign Go 出貨的高使用率上。
EMEA growth programs are customized by market and customers' type to encourage Invisalign utilization, such as Professional 360 Ortho and Advance 360 Ortho programs with over 2,000 orthodontist enrolled. We also had GP Move 360, a program design to be able to help move doctors along their developmental journey, with an increase in GP cohorts of over 117% compared to a prior year. We're also continuing to offer online and on-demand education events, which have reached over 15,000 GPs cumulatively.
EMEA 的成長計畫會依市場與客戶類型量身打造,以鼓勵 Invisalign 的使用,例如 Professional 360 Ortho 與 Advance 360 Ortho 計畫,已有超過 2,000 名矯正醫師加入。我們也推出 GP Move 360,該計畫旨在協助醫師在其發展旅程中持續進階,GP 分組(cohorts)相較前一年增加超過 117%。我們也持續提供線上與隨選教育活動,累計已觸及超過 15,000 名 GP。
In the region, we hosted several successful summits and forums for Invisalign doctors this quarter in all-virtual formats: the U.K. GP Forum and Ortho Summit, French Ortho Summit and the iTero Element Plus launch media event. In addition, we just held the Italian and DACH or German Ortho Summits last week.
在本區域內,本季我們以全虛擬形式舉辦了多場成功的 Invisalign 醫師高峰會與論壇:英國 GP Forum 與 Ortho Summit、法國 Ortho Summit,以及 iTero Element Plus 上市媒體活動。此外,我們也在上週剛舉辦義大利與 DACH(或德國)Ortho Summits。
International expansion remains one of our key strategic pillars. Last week, we announced plans to open a new manufacturing facility in Poland, which will be our first Aligner plant in the EMEA region and our third plant worldwide joining Juarez, Mexico and Ziyang, China. The new facility is expected to be supplying customers in the EMEA region in early 2022, helping address the large and relatively untapped market of more than 5 million annual orthodontic case starts and more than 150 million EMEA customers who could benefit from treatment. The investment is part of our strategy to bring operational facilities closer to our customers and reflects our commitment to Invisalign-trained doctors and their patients in the EMEA region and extends our local operations in the region.
國際擴張仍是我們關鍵的策略支柱之一。上週,我們宣布計畫在波蘭設立新的製造工廠,這將是我們在 EMEA 地區的第一座 Aligner 工廠,也是全球第三座工廠,與墨西哥華雷斯(Juarez)及中國資陽(Ziyang)並列。預期新廠將於 2022 年初開始為 EMEA 地區客戶供貨,協助因應每年超過 500 萬例矯正新啟動病例、以及超過 1.5 億名可能受益於治療的 EMEA 客戶所構成的龐大且相對尚未充分開發的市場。此項投資是我們將營運設施更貼近客戶策略的一部分,並反映我們對 EMEA 地區 Invisalign 受訓醫師及其患者的承諾,同時也擴展我們在當地的營運布局。
The state-of-the-art EMEA plant in Wroclaw is expected to have more than 2,500 jobs by the end of 2025, making it the company's largest investment in EMEA to date and the largest 3D printing operation in the region.
位於弗羅茨瓦夫(Wroclaw)的先進 EMEA 工廠,預計到 2025 年底將提供超過 2,500 個工作機會,成為公司迄今在 EMEA 最大的投資案,亦將是該地區最大的 3D 列印營運據點。
For APAC, Q1 volumes were down sequentially 3.9% as expected, reflecting seasonality. On a year-over-year basis, APAC was up 101.3% compared to the prior year, reflecting continued strong growth across the region, led by China, Japan and ANZ. Invisalign volume growth drivers were young adults, with young kids ramping faster than any other age group. In the teen segment, Invisalign volumes accelerated during the quarter and were driven by increased Invisalign utilization and case submissions from Invisalign doctors. We also continue to see good adoption of the Invisalign Moderate product for noncomprehensive treatment in the GP channel. During the quarter, we continued to offer online and on-demand education events which reached over 14,000 GPs cumulatively.
在 APAC 地區,第一季量能如預期較前一季下降 3.9%,反映季節性因素。以年對年來看,APAC 較前一年成長 101.3%,反映區域內持續強勁的成長,主要由中國、日本與 ANZ 帶動。Invisalign 量能成長的驅動因素為年輕成人,而年幼兒童的成長速度快於其他任何年齡層。在青少年族群方面,Invisalign 量能於本季加速成長,主要由 Invisalign 醫師提高使用率與病例提交量所帶動。我們也持續看到 GP 通路對 Invisalign Moderate 產品(用於非綜合性治療)的良好採用情況。本季我們持續提供線上與隨選教育活動,累計已觸及超過 14,000 名 GP。
Invisalign volumes in China were flat sequentially and up over 200% year-over-year. In Q1, China volumes gained momentum throughout the quarter. The Align clinical education site is the go-to digital hub for Invisalign doctors and team education and training. The digital learning environment was relaunched in February 2020 for Invisalign doctors, offering a comprehensive learning platform with role-specific content for orthos, GPs and their teams. The site enables more online learning opportunities with spotlight features for what's trending now, recommended learning paths based on doctors' experiences and expanded categories, including digital treatment planning, comprehensive dentistry and team education.
中國的 Invisalign 量能較前一季持平,年對年成長超過 200%。在第一季,中國量能在整個季度中逐步增強動能。Align 臨床教育網站是 Invisalign 醫師及其團隊進行教育與訓練的首選數位樞紐。該數位學習環境於 2020 年 2 月為 Invisalign 醫師重新上線,提供一個全面的學習平台,包含針對矯正醫師、GP 及其團隊的角色別內容。該網站提供更多線上學習機會,具備「目前趨勢」的焦點功能、依醫師經驗推薦的學習路徑,以及擴充的分類,包括數位治療規劃、綜合牙科與團隊教育。
During the quarter, over 102,000 unique users, having accessed the records lecture, completed self-paced learning modules and watched how-to videos, viewing more than 3 million pages of learning content. On the Ortho channel, over 38,000 unique users have engaged with a digital learning site and additional 63,000 unique users from the GP channel.
本季期間,超過 102,000 名不重複使用者曾造訪該網站,存取錄製課程、完成自學模組並觀看教學影片,瀏覽超過 300 萬頁的學習內容。在矯正通路方面,超過 38,000 名不重複使用者與數位學習網站互動;另有來自 GP 通路的 63,000 名不重複使用者。
We also continue to see good adoption of the ADAPT program, which is an expert and independent fee-based business consulting service offered by Align to optimize clinics' operational workflow and processes to enhance patient experience, customer and staff satisfaction. As a result of the ADAPT service, practices experience higher growth and greater efficiencies for orthodontic practices as well as improved profitability after implementation. To date, we've seen a 50% increase in Invisalign cases among doctors' cohorts within 6 months of participation in the ADAPT program. In addition, while still early in the program, we're also seeing a strong correlation or halo effect on teen utilization among ADAPT doctor cohorts.
我們也持續看到 ADAPT 計畫的良好採用情況。ADAPT 是 Align 提供的專家且獨立的付費商業顧問服務,旨在優化診所的營運工作流程與流程,以提升患者體驗、客戶與員工滿意度。導入 ADAPT 服務後,診所通常可在矯正業務上實現更高成長與更高效率,並在實施後改善獲利能力。迄今為止,我們觀察到醫師分組在參與 ADAPT 計畫後 6 個月內,Invisalign 病例數增加 50%。此外,雖然該計畫仍處於早期階段,我們也看到 ADAPT 醫師分組在青少年使用率方面呈現強烈的相關性或「光環效應」。
On consumer marketing, this focuses on educating consumers about the Invisalign system and driving that demand to our Invisalign doctor offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles.
在消費者行銷方面,我們的重點是教育消費者了解 Invisalign 系統,並將需求導流至我們的 Invisalign 醫師診所,最終把握將 5 億個笑容轉變的龐大市場機會。
In Q1, we continue to see strong digital engagement globally with more than 138% increase in unique visitors, 95% increase in doctor locator searches and 35% increase in leads created on a year-over-year basis, driven by our global adult and mom-focused campaigns and teen-focused influencer content. Our U.S. Mom/Teen multitouch, multimillion-dollar campaign with influencer-led YouTube videos, a mom-focused TV spot, a custom Twitch activation and mega teen sensations such as Charli D'Amelio and Avani Gregg continued to perform well and garnered 4.2 billion impressions in Q1.
第一季,我們持續看到全球數位互動表現強勁:不重複訪客數年對年增加超過 138%,醫師搜尋定位(doctor locator)查詢量增加 95%,以及建立的潛在客戶(leads)增加 35%。上述成長主要由我們全球成人與媽媽導向的行銷活動,以及青少年導向的網紅內容所帶動。我們在美國推出的 Mom/Teen 多觸點、數百萬美元級行銷活動(包含網紅主導的 YouTube 影片、以媽媽為主的電視廣告、自訂 Twitch 活動,以及 Charli D'Amelio 與 Avani Gregg 等超人氣青少年創作者)持續表現良好,並在第一季累計獲得 42 億次曝光(impressions)。
The statistics I shared previously speak to the continued success this marketing campaign is having to not only drive demand with consumers but also educate them on the benefits of Invisalign treatment through a doctor's office.
我先前分享的統計數據顯示,這項行銷活動持續取得成功,不僅能帶動消費者需求,也能透過牙醫診所教育消費者了解 Invisalign 治療的益處。
The Align Digital Platform continues to gain traction globally. Our consumer and patient app, My Invisalign, is now available in 58 markets, resulting in a more than 4x increase in app downloads and 3x increase in patients actively using our app in Q1 '21 versus the same period a year ago. Our consumer and patient feature usage continues to increase. For example, Invisalign Virtual Appointment Tool was used 86,000 times and our insurance verification feature was used 27,000 times in Q1. Further, we received more than 575,000 patient photos in our Virtual Care feature to date globally, providing us rich data to leverage our AI capabilities to improve our services for doctors and patients.
Align 數位平台持續在全球獲得動能。我們的消費者與患者 App「My Invisalign」目前已在 58 個市場上線,使得 2021 年第一季的 App 下載量較去年同期增加逾 4 倍,且實際活躍使用 App 的患者人數增加 3 倍。我們的消費者與患者功能使用率也持續提升。例如,Invisalign 虛擬約診工具在第一季被使用 86,000 次,而保險驗證功能被使用 27,000 次。此外,截至目前我們在全球的 Virtual Care 功能已收到超過 575,000 張患者照片,為我們提供豐富數據,以運用 AI 能力改善對醫師與患者的服務。
Lastly, our new consumer website has been rolled out to more than 50 markets and continues to drive increased effectiveness in lead creation. In the EMEA region, we built on the tremendous success we saw with the consumer marketing pilot in Q4 in the U.K. and expanded our media investments across the U.K., Germany and France to drive engagements, resulting in more than 335% increase in unique visitors and a 95% increase in leads.
最後,我們的新消費者網站已在超過 50 個市場推出,並持續提升名單(lead)創造的成效。在 EMEA 地區,我們延續第四季在英國進行消費者行銷試點所見的巨大成功,並擴大在英國、德國與法國的媒體投資以提升互動,帶動獨立訪客數增加逾 335%,名單數增加 95%。
We also expanded our consumer advertising in the APAC region in Australia, Japan and China, and saw more than a 2,000% increase in consumer engagement and a 298% increase in leads. Several key metrics that show increased activity engagement with Invisalign brand are included in our Q1 quarterly presentation slides available on our website.
我們也在亞太(APAC)地區的澳洲、日本與中國擴大消費者廣告投放,並看到消費者互動增加逾 2,000%,名單數增加 298%。多項顯示 Invisalign 品牌互動活動提升的關鍵指標,已收錄於我們網站上提供的第一季季度簡報投影片中。
Our NFL partnership continues to do well, generating over 23.5 million impressions during the quarter. It continues to be another major integral channel to reach adults considering clear aligner treatment through an Invisalign-trained doctor. During the quarter, we expanded our sports partnership marketing strategy with the Invisalign brand named the official smile partner of the Golden State Warriors. As part of the agreement with the 6x NBA Champion Golden State Warriors, the Invisalign brand also is the official smile partner of the Santa Cruz Warriors, the Golden State's G League affiliate, and the Golden Guardians, its e-sport affiliate. The sponsorship includes an omnichannel activation across TV, digital media, social, a jersey partnership with the Golden Guardians and the Santa Cruz Warriors.
我們與 NFL 的合作夥伴關係持續表現良好,本季產生超過 2,350 萬次曝光。這仍是另一個重要且不可或缺的渠道,用以觸及正在考慮透過受 Invisalign 訓練的醫師進行透明矯正器治療的成人。本季我們也擴大運動合作夥伴行銷策略,讓 Invisalign 品牌成為金州勇士隊的官方微笑合作夥伴。依據與 6 度 NBA 冠軍金州勇士隊的協議,Invisalign 品牌同時也是其 G League 附屬球隊 Santa Cruz Warriors,以及其電競附屬隊伍 Golden Guardians 的官方微笑合作夥伴。此贊助包含跨通路(omnichannel)啟動,涵蓋電視、數位媒體、社群,以及與 Golden Guardians 與 Santa Cruz Warriors 的球衣合作。
Finally, on the consumer marketing front, we also launched our first ever social purpose initiative in Q1 called Invisalign ChangeMakers, an award program we developed in partnership with the National 4-H Council. This is to celebrate and highlight teens in making an impact in their communities. We were blown away by the number of recommendations and stories we received about teens, from redistributing excess food to combat hunger in their communities, to donating weighted blankets to those in the autism spectrum. Overall, it's been heartwarming to learn about each of these amazing teenagers who bring a unique approach to positively impacting their communities and following their passions to create change.
最後,在消費者行銷方面,我們也於第一季推出首個社會公益倡議「Invisalign ChangeMakers」,這是一項我們與 National 4-H Council 合作開發的獎項計畫,用以表揚並凸顯在社區中帶來影響力的青少年。我們對收到的推薦數量與青少年故事感到非常驚艷,內容從重新分配多餘食物以對抗社區飢餓,到捐贈加重毯給自閉症光譜族群。整體而言,能了解每一位以獨特方式為社區帶來正向影響、並追隨熱情創造改變的優秀青少年,令人感到溫暖。
In total, we received nearly 800 ChangeMaker (sic) [ChangeMakers] applications. On June 28, we will announce 100 winners, each of whom will receive $5,000 to help them continue their goodwill efforts. We'll also celebrate these young forces of change with a virtual ceremony currently slated for mid-July.
總計我們收到近 800 份 ChangeMaker(原文如此)[ChangeMakers] 申請。6 月 28 日我們將公布 100 位得主,每位將獲得 5,000 美元,以協助他們持續推動善行。我們也將以預計於 7 月中旬舉行的線上典禮,表揚這些年輕的改變力量。
We are continuing to invest in creating consumer demand for Invisalign Aligners in markets around the world. Our global campaigns include a multichannel media strategy using digital video, social media, influencer marketing and TV.
我們持續投資於在全球各市場創造對 Invisalign 矯正器的消費者需求。我們的全球行銷活動包含多渠道媒體策略,運用數位影片、社群媒體、網紅行銷與電視。
For our Systems and Services business, Q1 revenues were up 5.8% sequentially, reflecting slightly lower scanner volume following a record fourth quarter. This is primarily due to the seasonality of capital equipment sales at year-end and higher services revenue. On a year-over-year basis, Systems and Services revenues were up 104%, reflecting strong scanner shipments and services.
在系統與服務(Systems and Services)業務方面,第一季營收較前一季成長 5.8%,反映在創紀錄的第四季之後,掃描儀出貨量略為下降。這主要是由於年底資本設備銷售的季節性因素,以及服務營收較高。以年對年來看,系統與服務營收成長 104%,反映掃描儀出貨強勁與服務表現。
The iTero Element 5D Imaging System continues to gain traction across all regions. Element 5D is the first integrated dental imaging system that simultaneously records 3D intra-oral optical impressions, 2D color images and Near Infrared technology (sic) [Near Infrared Images] or NIRI technology. Full arch scans can be completed in as little as 60 seconds, and NIRI technology scans the structure of the tooth in real-time without harmful radiation, acting as digital aid for detection of interproximal caries, or cavities, above the gingiva line.
iTero Element 5D 影像系統持續在各地區獲得採用。Element 5D 是首個整合式牙科影像系統,可同時記錄 3D 口內光學印模、2D 彩色影像,以及近紅外線技術(原文如此)[Near Infrared Images] 或 NIRI 技術。全口掃描最快僅需 60 秒即可完成,而 NIRI 技術可在無有害輻射的情況下即時掃描牙齒結構,作為數位輔助工具,用於偵測牙齦線以上的鄰接面齲齒(蛀牙)。
In APAC, the Element Flex is doing well with its wand-only configuration that provides needed mobility so doctors can see patients anywhere they choose and also or perform full arch scans in even the smallest office.
在亞太地區,Element Flex 以僅手持掃描棒(wand-only)的配置表現良好,提供所需的機動性,讓醫師可在任何選擇的地點為患者看診,並且也能在最小的診所內完成全口掃描。
During the quarter, we announced availability of the iTero Element Plus series, which expands the iTero portfolio to serve a broad range of the dental market. The new Element Plus series offers faster processing time, advanced visualization capabilities for a seamless scanning experience in a new sleek ergonomically-designed package. It's also engineered with the latest computing power, a dedicated AI chip and new AI-based features as well as an easy upgrade path for future innovation.
本季我們宣布 iTero Element Plus 系列正式上市,擴展 iTero 產品組合,以服務更廣泛的牙科市場。全新 Element Plus 系列在全新俐落且符合人體工學設計的機身中,提供更快的處理時間與進階視覺化能力,帶來更順暢的掃描體驗。其亦採用最新運算效能、專用 AI 晶片與新的 AI 功能設計,並提供便捷的升級路徑以支援未來創新。
In terms of digital scans used for Invisalign case submissions in Q1, total digital scans increased to 80.9% from 75.8% in Q1 last year. International scans increased to 75.1%, up from 68.7% in the same quarter last year. For the Americas, 85.5% of the cases submitted digitally compared to 80.5% a year ago. Cumulatively, over 35.4 million orthodontic scans and 7.5 million restorative scans have been performed with iTero scanners.
就第一季用於 Invisalign 病例提交的數位掃描而言,數位掃描占比由去年第一季的 75.8% 提升至 80.9%。國際市場掃描占比提升至 75.1%,高於去年同季的 68.7%。美洲地區方面,數位提交的病例占比為 85.5%,高於一年前的 80.5%。累計而言,使用 iTero 掃描儀已完成超過 3,540 萬次齒顎矯正掃描與 750 萬次修復掃描。
Turning to exocad. A year ago in April, we welcomed exocad into the Align family. I want to thank the entire team for their continued progress on integration and road map development. Together, we are working to extend exocad's position as a key technology provider for the dental CAD/CAM industry and to drive continuous innovation with the open and integrated approach that is the foundation of exocad.
接著談 exocad。一年前的 4 月,我們歡迎 exocad 加入 Align 大家庭。我想感謝整個團隊在整合與產品路線圖開發方面持續取得進展。我們正共同努力,延伸 exocad 作為牙科 CAD/CAM 產業關鍵技術供應商的地位,並以 exocad 所奠基的開放且整合式方法,推動持續創新。
During Q1, the new release of exocad's DentalCAD 3D (sic) [DentalCAD3.0] Galway was successfully rolled out globally with very positive customer feedback. A record number of over 70,000 verified prosthetic components were created in DentalCAD Galway, one of the largest prosthetic libraries in the industry.
第一季期間,exocad 全新版本 DentalCAD 3D(原文如此)[DentalCAD3.0] Galway 已成功在全球推出,並獲得非常正面的客戶回饋。DentalCAD Galway 建立了創紀錄、超過 70,000 個已驗證的義齒元件,成為業界最大的義齒元件資料庫之一。
exocad also reached a new milestone for the exoplan database, which now supports nearly 10,000 implants from over 90 manufacturers. The new release also includes a unique and highly innovative DentalCAD feature, Instant Anatomic Morphing, that reduces design time by up to 30% compared to previous version. It also includes new AI technology for exocad's Smile Creator, which enables time-saving automatic detection of facial features.
exocad 也在 exoplan 資料庫達成新的里程碑,目前已支援來自 90 多家製造商、近 10,000 種植體。新版本亦包含一項獨特且高度創新的 DentalCAD 功能「Instant Anatomic Morphing」,相較前一版本可將設計時間最多縮短 30%。此外也為 exocad 的 Smile Creator 納入新的 AI 技術,可自動偵測臉部特徵以節省時間。
In addition, the new MyiTero Connector was launched directly to exocad labs. The MyiTero Connector creates an easy and integrated way to receive intra-oral scan cases from thousands of iTero doctors worldwide. New cases are downloaded automatically and will show up directly in the DentalDB case list.
此外,全新的 MyiTero Connector 已直接向 exocad 實驗室推出。MyiTero Connector 提供一種簡單且整合的方式,可接收來自全球數千位 iTero 醫師的口內掃描病例。新病例會自動下載,並直接顯示於 DentalDB 病例清單中。
exocad also co-hosted a joint dentistry event in the U.K. to showcase full workflow with chairside (sic) [ChairsideCAD] titled Digital Dentistry Hands On. The virtual roadshow aimed at general dentists showcases a full digital workflow for the clinical environment with ChairsideCAD, exocad's complete open architecture CAD software platform for single-visit dentistry. Hosted by Dr. Gulshan Murgai, the participants of the roadshow series learn how to use the software for single-visit restorations and implant planning in the dental practice along the entire digital dentistry workflow.
exocad 也在英國共同主辦一場聯合牙科活動,以展示名為 Digital Dentistry Hands On 的完整椅旁(原文如此)[ChairsideCAD] 工作流程。此線上巡迴展面向一般牙醫師,展示在臨床環境中使用 ChairsideCAD 的完整數位工作流程;ChairsideCAD 是 exocad 用於單次就診牙科的完整開放式架構 CAD 軟體平台。該活動由 Gulshan Murgai 醫師主持,巡迴系列的參與者將學習如何在整個數位牙科工作流程中,於牙科診所使用該軟體進行單次就診修復與植體規劃。
These are just a few milestones, and we're excited about the opportunities ahead to shape the dental industry with technology and expertise that benefits all customers, labs, partners and users. We look forward to sharing more about ongoing exocad developments.
以上僅是部分里程碑。我們對未來能以科技與專業塑造牙科產業、並讓所有客戶、技工所、合作夥伴與使用者受益的機會感到振奮。我們也期待分享更多關於 exocad 持續開發的進展。
With that, I'll now turn it over to John.
接下來,我把時間交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe.
謝謝你,Joe。
Now for our Q1 financial results. Total revenues for the first quarter were $894.8 million, up 7.2% from the prior quarter and up 62.4% from the corresponding quarter a year ago. For Clear Aligners, Q1 revenues of $753.3 million were up 7.5% sequentially and up 56.4% year-over-year, reflecting Invisalign volume growth in most geographies. Clear Aligner revenue growth was favorably impacted by foreign exchange of approximately $14.4 million or approximately 2.1 points sequentially and on a year-over-year basis, by approximately $22.3 million or approximately 4.6 points.
接著說明我們第一季(Q1)的財務結果。第一季總營收為 8.948 億美元,較前一季成長 7.2%,較去年同期成長 62.4%。在透明牙套(Clear Aligners)方面,第一季營收為 7.533 億美元,季增 7.5%、年增 56.4%,反映 Invisalign 在多數地區的出貨量成長。透明牙套營收成長在季比方面受匯率影響帶來約 1,440 萬美元(約 2.1 個百分點)的正面貢獻;在年比方面則受匯率影響帶來約 2,230 萬美元(約 4.6 個百分點)的正面貢獻。
For Q1, Invisalign Comprehensive and Non-Comprehensive ASPs were both up sequentially. On a year-over-year basis, Q1 Invisalign Comprehensive and Non-Comprehensive ASP decreased. Overall, on a sequential and year-over-year basis, ASPs were favorably impacted by foreign exchange. On a year-over-year basis, ASPs were impacted by higher net revenue deferrals in all regions and higher promotional discounts.
第一季 Invisalign Comprehensive 與 Non-Comprehensive 的平均銷售單價(ASP)均較前一季上升。以年比來看,第一季 Invisalign Comprehensive 與 Non-Comprehensive 的 ASP 則下降。整體而言,無論季比或年比,ASP 皆受到匯率的正面影響。以年比來看,ASP 亦受到各區域較高的淨營收遞延,以及較高的促銷折扣所影響。
Clear aligner deferred revenue on the balance sheet increased $79 million sequentially and $256 million year-over-year and will be recognized as the additional aligners are shipped. Total Q1 clear aligner shipments of 595,800 cases were up 4.9% sequentially and up 65.8% year-over-year.
資產負債表上的透明牙套遞延營收較前一季增加 7,900 萬美元,較去年同期增加 2.56 億美元,並將在額外牙套出貨時認列。第一季透明牙套總出貨量為 595,800 例,季增 4.9%、年增 65.8%。
Our Systems and Services revenues for the first quarter was a record $141.5 million, up 5.8% sequentially due to product mix and increased services revenues from our larger installed base and exocad's CAD/CAM services. Year-over-year, Systems and Services revenues was up 104% due to higher scanner shipments and services and the inclusion of exocad's CAD/CAM services from the April 2020 acquisition and increased services from our larger installed base.
第一季系統與服務(Systems and Services)營收創新高,達 1.415 億美元,季增 5.8%,主要因產品組合,以及因安裝基數擴大與 exocad 的 CAD/CAM 服務帶動服務營收增加。年比方面,系統與服務營收成長 104%,主要因掃描器出貨量與服務增加、納入 2020 年 4 月收購 exocad 所帶來的 CAD/CAM 服務,以及因安裝基數擴大而增加的服務營收。
Our Systems and Services deferred revenue was up 17% sequentially and up 102% year-over-year, primarily due to the increase in scanner sales and the deferral of service revenues, which will be recognized ratably over the service period.
系統與服務遞延營收季增 17%、年增 102%,主要因掃描器銷售增加,以及服務營收遞延;該等遞延服務營收將於服務期間按期平均認列。
Moving on to gross margin. First quarter overall gross margin was 75.7%, up 2.5 points sequentially and up 4.1 points year-over-year. On a non-GAAP basis, excluding stock-based compensation and amortization of intangibles related to our exocad acquisition, overall gross margin was 76.1% for the first quarter and up 2.5 points sequentially and up 4.2 points year-over-year. Overall gross margin was favorably impacted by approximately 0.5 points sequentially and 0.7 points on a year-over-year basis due to foreign exchange.
接著看毛利率。第一季整體毛利率為 75.7%,較前一季上升 2.5 個百分點,較去年同期上升 4.1 個百分點。以非 GAAP 基礎(排除以股份為基礎之酬勞,以及與收購 exocad 相關的無形資產攤銷)計算,第一季整體毛利率為 76.1%,較前一季上升 2.5 個百分點,較去年同期上升 4.2 個百分點。整體毛利率亦受匯率影響,季比約增加 0.5 個百分點、年比約增加 0.7 個百分點。
Clear Aligner gross margin for the first quarter was 77.6%, up 2.7 points sequentially due to increased manufacturing efficiencies from higher production volumes, higher ASPs and lower freight, partially offset by higher additional aligner volume. Clear Aligner gross margin was up 4.6 points year-over-year due to increased manufacturing efficiencies from higher production volumes and lower freight, partially offset by lower ASPs.
第一季透明牙套毛利率為 77.6%,較前一季上升 2.7 個百分點,主要因較高產量帶來的製造效率提升、ASP 提高與運費降低,但部分被額外牙套出貨量增加所抵銷。透明牙套毛利率年增 4.6 個百分點,主要因較高產量帶來的製造效率提升與運費降低,但部分被 ASP 下降所抵銷。
Systems and Services gross margin for the first quarter was a record 65.4%, up 1.2 points sequentially, primarily due to manufacturing efficiencies from higher production volumes and higher ASPs, partially offset by increased freight. Systems and Services gross margin was up 3.6 points year-over-year due to manufacturing efficiencies from increased volume, higher ASPs and services revenues.
第一季系統與服務毛利率創新高,達 65.4%,較前一季上升 1.2 個百分點,主要因較高產量帶來的製造效率提升與 ASP 提高,但部分被運費增加所抵銷。系統與服務毛利率年增 3.6 個百分點,主要因出貨量增加帶來的製造效率提升、ASP 提高以及服務營收增加。
Q1 operating expenses were $451.7 million, up sequentially 13.7% and up 39.2% year-over-year. The sequential increase in operating expenses is due to increased compensation, primarily from additional headcount and incentive compensation, consumer marketing spend and other general and administrative costs. Year-over-year, operating expenses increased by $127.2 million, reflecting our continued investment in sales and R&D activities and investments commensurate with business growth.
第一季營業費用為 4.517 億美元,季增 13.7%、年增 39.2%。營業費用的季比增加主要因薪酬增加(主要來自新增人力與獎酬)、消費者行銷支出,以及其他一般與行政成本。年比方面,營業費用增加 1.272 億美元,反映我們持續投資於銷售與研發活動,並依業務成長進行相應投資。
On a non-GAAP basis, which excludes stock-based compensation, amortization of intangibles related to our exocad acquisition and acquisition costs related to our exocad acquisition, operating expenses were $424.8 million, up sequentially 14.1% and up 40.9% year-over-year.
以非 GAAP 基礎(排除以股份為基礎之酬勞、與收購 exocad 相關的無形資產攤銷,以及與收購 exocad 相關的收購成本)計算,營業費用為 4.248 億美元,季增 14.1%、年增 40.9%。
Our first quarter operating income of $225.4 million resulted in an operating margin of 25.2%, down 0.3 points sequentially and up 12.5 points year-over-year. The sequential decrease in operating margin is attributed to operational investments. The year-over-year increase in operating margin are primarily attributed to higher gross margin and operating leverage.
第一季營業利益為 2.254 億美元,營業利益率為 25.2%,較前一季下降 0.3 個百分點,較去年同期上升 12.5 個百分點。營業利益率的季比下降歸因於營運投資。營業利益率的年比上升主要歸因於毛利率提高與營運槓桿效益。
On a non-GAAP basis, which excludes stock-based compensation and amortization of intangibles, the acquisition costs related to our exocad acquisition, operating margin for the first quarter was 28.6%, down 0.4 points sequentially and up 11.5 points year-over-year. Our operating margin was favorably impacted by approximately 0.8 points sequentially and 1.5 points on a year-over-year basis due to foreign exchange.
以非 GAAP 基礎(排除以股份為基礎之酬勞與無形資產攤銷,以及與收購 exocad 相關的收購成本)計算,第一季營業利益率為 28.6%,較前一季下降 0.4 個百分點,較去年同期上升 11.5 個百分點。我們的營業利益率亦受匯率影響,季比約增加 0.8 個百分點、年比約增加 1.5 個百分點。
Interest and other income and expense, net, for the first quarter was a gain of $36.2 million, primarily driven by the SDC arbitration award gain. Excluding the SDC arbitration award gain, interest and other income and expense, net, was a $7.2 million expense on a non-GAAP basis.
第一季利息及其他收益與費用(淨額)為收益 3,620 萬美元,主要由 SDC 仲裁裁決收益所帶動。排除 SDC 仲裁裁決收益後,以非 GAAP 基礎計算,利息及其他收益與費用(淨額)為費用 720 萬美元。
With regards to the first quarter tax provision, our GAAP tax rate was 23.4%, which includes tax expense of approximately $11 million related to U.S. taxes on the SDC arbitration award received and approximately $14 million of excess tax benefits related to stock-based compensation. Our GAAP tax rate this quarter was lower than the prior quarter rate of 25.9%, primarily due to the higher excess tax benefits from stock-based compensation, partially offset by foreign income taxes at different rates.
就第一季所得稅費用而言,我們的 GAAP 有效稅率為 23.4%,其中包含約 1,100 萬美元(與收到 SDC 仲裁裁決款相關的美國稅負)以及約 1,400 萬美元(與以股份為基礎之酬勞相關的超額稅務利益)。本季 GAAP 有效稅率低於前一季的 25.9%,主要因以股份為基礎之酬勞帶來較高的超額稅務利益,但部分被不同稅率的海外所得稅所抵銷。
Our GAAP tax rate was higher than the same quarter last year, which was negative 2,745%, primarily due to a onetime tax benefit of approximately $1.5 billion associated with our corporate structure reorganization completed during the first quarter of 2020. The first quarter tax rate on a non-GAAP basis was 20.2% compared to 14.5% in prior quarter and 33.2% in the prior year. The first quarter non-GAAP tax rate was higher than the prior quarter rate, primarily due to lower tax benefits from foreign income tax at different rates. In comparison to prior year, the non-GAAP tax rate for the first quarter was lower primarily due to higher tax benefits from foreign income tax at different rates.
我們的 GAAP 有效稅率高於去年同期(為負 2,745%),主要因 2020 年第一季完成公司架構重組所帶來一次性約 15 億美元的稅務利益。以非 GAAP 基礎計算,第一季有效稅率為 20.2%,相較前一季為 14.5%、去年同期為 33.2%。第一季非 GAAP 有效稅率高於前一季,主要因不同稅率的海外所得稅所帶來的稅務利益較低。相較去年同期,第一季非 GAAP 有效稅率較低,主要因不同稅率的海外所得稅所帶來的稅務利益較高。
First quarter net income per diluted share was $2.51, up $0.51 sequentially and down $16.70 compared to prior year. On a non-GAAP basis, net income per diluted share was $2.49 for the first quarter, down $0.12 sequentially and up $1.76 year-over-year.
第一季稀釋後每股淨利為 2.51 美元,較前一季增加 0.51 美元,較去年同期減少 16.70 美元。以非 GAAP 基礎計算,第一季稀釋後每股淨利為 2.49 美元,較前一季減少 0.12 美元,較去年同期增加 1.76 美元。
Moving on to the balance sheet. As of March 31, 2021, cash and cash equivalents were $1.1 billion, an increase of approximately $170.9 million from the prior quarter, which is primarily due to cash flow from operations. Of our $1.1 billion of cash and cash equivalents, $684.4 million was held in the U.S. and $447.3 million was held by our international entities.
接著看資產負債表。截至 2021 年 3 月 31 日,現金及約當現金為 11 億美元,較前一季增加約 1.709 億美元,主要來自營運活動現金流。在 11 億美元的現金及約當現金中,6.844 億美元存放於美國,4.473 億美元由海外子公司持有。
Q1 accounts receivable balance was $719 million, up approximately 9.3% sequentially. Our overall days sales outstanding was 72 days, up approximately 1 day sequentially and down approximately 15 days as compared to Q1 last year. Cash flow from operations for the first quarter was $227.2 million. Capital expenditures for the first quarter were $43.4 million, primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow, defined as cash flow from operations less capital expenditures, amounted to $183.8 million.
第一季應收帳款餘額為 7.19 億美元,季增約 9.3%。整體應收帳款週轉天數(DSO)為 72 天,較前一季增加約 1 天,較去年第一季減少約 15 天。第一季營運活動現金流為 2.272 億美元。第一季資本支出為 4,340 萬美元,主要與我們持續投資以提升牙套產能與設施相關。自由現金流(定義為營運活動現金流減資本支出)為 1.838 億美元。
We also have $300 million available under our revolving line of credit. Under our May 2018 repurchase program, we have $100 million remaining available for repurchase of our common stock.
我們在循環信用額度項下亦有3億美元可用額度。依據我們於2018年5月的回購計畫,目前尚有1億美元可用於回購本公司普通股。
Now let me turn to our outlook. Overall, we are very pleased with our first quarter results and our continued strong momentum across regions and customer channels. It has been over a year since the pandemic began, and I want to briefly recap the actions we took to support our employees by protecting employee jobs and salaries and by supporting our customers with PPE, extended payment terms, training and many other areas of assistance.
現在讓我談談我們的展望。整體而言,我們對第一季的業績以及在各地區與客戶通路持續強勁的動能感到非常滿意。自疫情爆發以來已逾一年,我想簡要回顧我們為支持員工所採取的行動,包括保障員工工作與薪資,以及透過提供個人防護裝備(PPE)、延長付款條件、訓練與許多其他協助領域來支持我們的客戶。
Instead of going quiet, we accelerated our investments in marketing to drive consumer demand to our doctors' offices and stay top of mind with consumers. We accelerated our digital technology investments so that we could provide virtual tools to our doctors, enabling them to stay connected with their patients and keep their treatment moving forward. We continued to grow the business, increased our investments in R&D and product innovation and developing our plans for manufacturing expansion in EMEA. We did all these things for our customers, partners, employees and shareholders because we believe in the industry and the size of the market opportunity. Our results are the outcome of our conviction in our business model, focus and ability to execute.
我們沒有沉寂下來,反而加速投入行銷,以帶動消費者需求回到醫師診所,並在消費者心中保持首選地位。我們也加速數位科技投資,得以為醫師提供虛擬工具,使其能與病患保持連結並讓治療持續推進。我們持續擴大業務、增加研發與產品創新投資,並制定在EMEA擴充製造的計畫。我們為客戶、合作夥伴、員工與股東做了這些事,因為我們相信這個產業以及市場機會的規模。我們的成果反映了我們對商業模式的信念、專注以及執行能力。
While there continues to be uncertainty around the pandemic and global environment, the strength in our business reflects the purposeful decisions we made through the pandemic and fuels our confidence in continuing to invest into growth to drive demand and conversion globally.
儘管疫情與全球環境仍存在不確定性,我們業務的強勁表現反映了我們在疫情期間所做的有目的決策,並強化我們持續投入成長、在全球推動需求與轉換的信心。
Q2 is off to a great start and momentum has continued through April. Consumer demand trends and patient traffic across the dental industry are favorable and continue to improve. Given these factors and the positive trends we continue to see across the business, we believe it is important to share our current outlook and provide guidance for the full year. Note that the outlook we are providing does not reflect any potential significant disruption or additional costs related to any supply constraints.
第二季開局非常良好,動能也延續至4月。牙科產業的消費者需求趨勢與病患就診人流表現有利,且持續改善。基於這些因素以及我們在業務各面向持續看到的正向趨勢,我們認為有必要分享目前展望並提供全年指引。請注意,我們所提供的展望未反映任何可能因供應限制而造成的重大干擾或額外成本。
With that, let's turn to our full year 2021 outlook and the factors that inform our view. We have growing confidence in our digital platform and how it is driving growth across all regions and market segments. We expect 2021 revenues of $3.7 billion to $3.9 billion, up 50% to 58% year-over-year. Consistent with past years, we expect second half revenue to make up more than half of the full year revenue, and our second half revenue to grow year-over-year around the midpoint of our long-term operating model target of 20% to 30%.
接著,讓我們談談2021年全年展望以及支撐我們觀點的因素。我們對數位平台及其如何在所有地區與市場區隔帶動成長的信心日益提升。我們預期2021年營收為37億至39億美元,年增50%至58%。與過往年度一致,我們預期下半年營收將占全年營收的一半以上,且下半年營收年增率約落在我們長期營運模型目標20%至30%的中點附近。
As discussed during our last earnings call, we are increasing our investments in sales, marketing, innovation and manufacturing capacity to continue to drive our growth programs and accelerate adoption in a vastly underpenetrated market. On a GAAP basis, we anticipate 2021 and operating margin to be between 23.5% and 24.5%. On a non-GAAP basis, we expect 2021 operating margin to be approximately 3 points higher than our GAAP operating margin after excluding stock-based compensation and intangible amortization.
如同我們在上次財報電話會議中所討論,我們正增加在銷售、行銷、創新與製造產能方面的投資,以持續推動成長計畫,並在滲透率仍極低的市場中加速採用。以GAAP基礎計算,我們預期2021年營業利益率介於23.5%至24.5%。以非GAAP基礎計算,在排除以股份為基礎之薪酬與無形資產攤銷後,我們預期2021年營業利益率將較GAAP營業利益率高約3個百分點。
In addition, during Q2 '21, we expect to repurchase $100 million of our common stock through either open market repurchases or an accelerated stock repurchase agreement we intend to enter into on or prior to May 3, 2021. The repurchase is intended to complete the $600 million stock repurchase authorization announced on May 23, 2018.
此外,在2021年第二季期間,我們預期將透過公開市場回購或加速股票回購協議(我們擬於2021年5月3日當日或之前簽訂)回購1億美元的本公司普通股。此回購旨在完成我們於2018年5月23日宣布的6億美元股票回購授權。
For 2021, we expect our investments in capital expenditures to exceed $300 million. Capital expenditures primarily relate to building construction and improvements as well as additional manufacturing capacity to support our international expansion. This includes our planned investment in a new manufacturing facility in Wroclaw, Poland, our first one in the EMEA region. We intend to fund these needs with cash generated from operations.
就2021年而言,我們預期資本支出投資將超過3億美元。資本支出主要與建築興建與改善,以及為支持國際擴張而增加的製造產能相關。其中包括我們計畫投資於波蘭弗羅茨瓦夫(Wroclaw)新建製造設施,這將是我們在EMEA地區的第一座工廠。我們擬以營運所產生的現金來支應這些需求。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交回給Joe做最後評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John.
謝謝,John。
In summary, we're very pleased with the first quarter results of 2021. Our strong growth and continued momentum reflect our strategic initiatives and investments, including support for doctors to ensure treatment and business continuity, ramping availability of virtual tools to keep doctors and patients connected throughout treatment and increased consumer marketing and concierge programs. The benefits of digital treatment and digital tools and the limitations of outdated old analog approaches continue to drive adoption of Invisalign Clear Aligners and iTero scanners and services.
總結來說,我們對2021年第一季的業績感到非常滿意。我們的強勁成長與持續動能反映了我們的策略性倡議與投資,包括支持醫師以確保治療與營運的連續性、提升虛擬工具的可用性以在治療期間維持醫師與病患的連結,以及增加面向消費者的行銷與禮賓(concierge)計畫。數位治療與數位工具的效益,以及過時的傳統類比方式的限制,持續推動Invisalign隱形矯正器與iTero掃描儀及服務的採用。
Over the past year, more doctors have experienced Align's digital platform, which made it possible for thousands of Invisalign practices and patients to continue treatments throughout global disruption, thanks to Invisalign aligners, digital treatment planning, virtual monitoring and care as well as iTero scanners.
在過去一年中,更多醫師體驗了Align的數位平台;該平台使數以千計的Invisalign診所與病患得以在全球性干擾期間持續治療,這要歸功於Invisalign矯正器、數位治療規劃、虛擬監測與照護,以及iTero掃描儀。
But the shift from traditional analog wires and brackets to a fully end-to-end digital platform is not easy, cannot be done without very complex technology. And this technology is prevalent, touching every aspect of what we do from manufacturing excellence where we currently manufacture over 700,000 unique aligners per day, to expanding our geographic footprint to over 100 markets, to building a network of over 200,000 trained Invisalign doctors and providing the technology to our doctors in a complete digital system, the Aligned digital platform.
然而,從傳統的類比鋼線與托槽轉向完整端到端的數位平台並不容易,若沒有非常複雜的技術就無法做到。而這項技術無所不在,觸及我們所做的一切:從製造卓越(我們目前每天生產超過700,000副獨特的矯正器),到將地理版圖擴展至100多個市場,再到建立超過200,000名受訓的Invisalign醫師網絡,並以完整的數位系統——Aligned數位平台——向醫師提供技術。
As the market leader in the clear aligner space, we have been building this industry over 24 years to get to where it is today and yet the majority of the market opportunity remains largely untapped. With over 500 million potential case starts globally, Align is in a rare position to address this market with the Align Digital Platform, powered by 2 decades of clinical data based on more than 10.2 million patients with AI machine learning and digital tools to help our doctors efficiently communicate with their patients, show and explain any issues and visualize potential treatment outcomes. And together with doctors, we're going to leverage the power of digital dentistry and orthodontics more than ever.
作為透明矯正器領域的市場領導者,我們在過去24年持續打造這個產業,才走到今天的位置,但市場機會的大部分仍未被充分開發。全球潛在起始病例超過5億例,Align處於難得的有利位置,能以Align數位平台來切入此市場;該平台以20年的臨床資料為基礎,涵蓋超過1,020萬名病患,並結合AI機器學習與數位工具,協助醫師更有效率地與病患溝通、展示並解釋任何問題,以及視覺化潛在的治療結果。我們也將與醫師一起,比以往更充分地運用數位牙科與齒顎矯正的力量。
We remain focused on our strategic execution, agility, customer service excellence and continuing to make investments to grow our business to drive utilization of the Invisalign system, ultimately returning value to our shareholders. This is the multi-variable equation that we talk about and there's no other company in the market today that has all these capabilities combined.
我們仍專注於策略執行、敏捷性、卓越的客戶服務,並持續投資以擴大業務、提升Invisalign系統的使用率,最終為股東創造回報。這就是我們所談的多變數方程式,而目前市場上沒有任何其他公司能同時具備並整合所有這些能力。
Finally, throughout the pandemic, our priority has been the health and safety of our employees and their families and our doctor customers and their staff, and that has not changed. We remain dedicated to their well-being, and I want to reiterate our commitment to all Invisalign practices and our employees around the world, especially those in areas recently affected by a surge in COVID-19: India, Brazil, France, Poland, Ukraine, Mexico, Thailand and Japan. We are continuing to monitor the situations and are providing support and resources to those impacted employees.
最後,在整個疫情期間,我們的首要任務一直是員工及其家人、以及我們的醫師客戶與其員工的健康與安全,而這一點沒有改變。我們仍致力於他們的福祉,並希望再次重申我們對全球所有Invisalign診所與員工的承諾,特別是近期受COVID-19疫情激增影響的地區:印度、巴西、法國、波蘭、烏克蘭、墨西哥、泰國與日本。我們將持續監測情勢,並為受影響的員工提供支援與資源。
Thanks for your time today. I look forward to updating you on our progress as the year unfolds. Now I'll turn the call back over to the operator.
感謝各位今天撥冗參與。我期待在今年進展的過程中向各位更新我們的進度。現在我把電話交回給接線員。
Operator
Operator
(Operator Instructions) The first question is from Nathan Rich from Goldman Sachs.
(接線員指示)第一個問題來自高盛(Goldman Sachs)的Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Maybe starting with the guidance for the year and your expectations over the balance of the year. I appreciate the detail that you gave. I guess, should we think about the revenue cadence as being similar to a normal year? And Joe, I mean, it certainly seems like the shift in market share that you've been highlighting has accelerated during the pandemic. I guess I'd be curious to know if you have any way of kind of quantifying the magnitude of this shift as we think about the ability of -- you just kind of sustain this momentum going forward and the gains that obviously Clear Aligners has had during the pandemic.
或許先從全年指引以及你們對今年剩餘期間的預期談起。我很感謝你提供的細節。我想問的是,我們是否應該把營收的節奏視為與正常年度相近?另外,Joe,我的意思是,你一直強調的市占率轉移在疫情期間似乎加速了。我想知道你是否有任何方式可以量化這種轉移的幅度,以便我們評估——你們在未來持續維持這股動能的能力,以及透明矯正器在疫情期間顯然取得的增長。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
All right. Nathan, we're obviously optimistic. I mean, given the guidance we had today and the strong first quarter results, we really feel good about where we are. The great thing about this growth is it's been broad and deep, okay? It is across every region. We see it whether it's in APAC, or whether it's EMEA, whether it's in the Americas overall. And then across the GP spectrum, across the ortho spectrum, too, it's been terrific. And it's also up and down. That's why we're giving you comprehensive, noncomprehensive now, all different kinds of cases.
好的。Nathan,我們顯然是樂觀的。我的意思是,考量我們今天給出的指引以及第一季強勁的業績,我們對目前的狀況感到非常良好。這波成長最棒的地方在於它既廣且深,好嗎?它遍及每個地區。我們在亞太(APAC)看到,在EMEA看到,在美洲整體也看到。然後在一般牙科(GP)範疇、在齒顎矯正(ortho)範疇也都表現非常出色。而且它也上下延伸。這就是為什麼我們現在提供給你更全面、非全面的——各種不同類型的病例。
So we just feel great about the demand patterns, the depth and breadth of this rebound and that's why we have some clarity now. We decided to give guidance, and we're excited about this year and going forward. John, any thoughts on it?
所以我們對需求型態、這波反彈的深度與廣度都感到非常振奮,這也是為什麼我們現在有了一些清晰度。我們決定提供財測指引,並且對今年以及未來的發展感到興奮。John,你有什麼想法嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And to add to your question, Nathan, the seasonality and things that we've seen in the past will continue. We would expect those to continue as we go through this year. So it's hard to compare year-over-year, especially in the first half. But going forward, it makes sense to look at it quarter-over-quarter.
再補充你的問題,Nathan,我們過去看到的季節性等因素將會延續。我們預期今年接下來也會持續如此。所以要做年對年比較很困難,尤其是在上半年。但往後看,以季對季來觀察會更合理。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Great. And if I could just ask a quick follow-up on the -- it seems like it's going to -- there's going to be more discussion around comprehensive versus noncomprehensive instead of the regional breakout going forward. So I was wondering if you could just level set us on the current mix of business between comprehensive and non-comprehensive cases. And how you're thinking about the growth of those 2 categories going forward?
很好。如果我可以再快速追問一下——看起來未來討論的重點,會從區域拆分轉向「全方位(comprehensive)」與「非全方位(noncomprehensive)」的比較。因此我想請你們先幫我們校準一下,目前業務組合中,全方位與非全方位案例的占比各是多少?以及你們如何看待未來這兩個類別的成長?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. When you look at it, Nathan, it's about 75% comprehensive, 25% noncomprehensive. It can vary by quarter based on teen season and so on, but that's roughly the split there. And we're investing in both areas to be able to grow, whether it's on the ortho side or the GP side for those categories.
是的。Nathan,從整體來看,大約是 75% 全方位、25% 非全方位。這個比例可能會因季度、青少年季等因素而有所波動,但大致就是這樣的分布。我們也在兩個領域都持續投資以推動成長,不論是在矯正科(ortho)端或一般牙科(GP)端,針對這些類別都會投入。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
And Nate, I think you know the margin on those products also. So there's not -- this is not like a margin split. I mean, you still have higher margins on the less than comprehensive product line, too. So it's a good mix.
Nate,我想你也了解這些產品的毛利狀況。所以這並不是一個毛利拆分的問題。我的意思是,較非全方位的產品線毛利也更高。因此這是一個不錯的組合。
Operator
Operator
The next question is from Jason Bednar from Piper Sandler.
下一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Congrats on a really nice quarter here. I actually want to start on guidance as well. If I focus in the second half of the year, maybe when comps tend to normalize a bit and use the midpoint of that 20% to 30% long-term guide you've got out there. Are you able to talk about how this comes together from a regional or channel perspective? Is it safe to assume that teens international still grows above that mid-20s level? And then is it right to think about imaging and CAD/CAM growing at that mid-20s level as well?
恭喜本季表現非常亮眼。我也想先從財測指引談起。如果我聚焦在下半年——也許那時比較基期會更趨於正常——並以你們提出的 20% 到 30% 長期指引區間的中點來看。你們能否談談,從區域或通路角度,這個成長是如何組成的?是否可以假設國際市場的青少年(teens)仍會高於 20% 中段的成長?另外,影像與 CAD/CAM 也會以 20% 中段的速度成長嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Jason, this is John. We would look at Invisalign and our System and Services to grow at that midpoint in the second half, so around that 25% year-over-year across the business. And we're making investments and continued investments, as we've talked about, to really establish and continue our growth.
Jason,我是 John。我們預期 Invisalign 以及我們的系統與服務(System and Services)在下半年會以中點水準成長,也就是全公司年對年約 25% 左右。我們也如同先前所談,正在進行投資並持續加碼投資,以真正建立並延續我們的成長。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Okay. And John, just sorry, anything from a regional or channel perspective, international or teens or just how that all comes together?
好的。John,不好意思再追問一下,有沒有任何從區域或通路角度的補充?例如國際、青少年,或是整體如何拼湊起來?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I think we're not forecasting by each of the regions and so on from that. I think you can -- from our business, we're trying to grow teens. It's a great indicator for the penetration on the ortho side, and we'll continue to grow that, but not giving specifics by region.
我想我們不會針對各區域等逐一做預測。我認為你可以看到——就我們的業務而言,我們正努力推動青少年成長。這是矯正科端滲透率的一個很好的指標,我們會持續推動,但不會按區域提供具體數字。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Okay. Understood. And then just one other follow-up. I mean, the Clear Aligner gross margin was extremely strong this quarter. The Clear Aligner revenue, that grew $50 million sequentially with COGS that fell by $10 million. John, I know you stepped through some of the factors just incorporated there. But is this a sustainable level that we should be thinking about for Clear Aligner gross margin going forward, kind of in this upper 70s level? Or maybe were there some other factors that helped push that gross margin higher here just in the first quarter?
了解。接著再一個追問。我的意思是,本季透明矯正器(Clear Aligner)毛利率非常強勁。透明矯正器營收較前一季增加了 5,000 萬美元,但銷貨成本(COGS)卻下降了 1,000 萬美元。John,我知道你剛剛已經逐項說明了一些因素。但這樣的透明矯正器毛利率水準,未來是否可持續?例如維持在 70% 後段這個區間?還是第一季有其他因素推升了毛利率?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Well, we did see some FX benefit, as we called out, but it's a reflection of investing in this business, adding capacity, adding in places where we see the growth, and this was leveraging some of that -- those investments. So it's a reflection of the work that we have, the productivity that we can drive across the business, utilizing some of the facilities that we have and then benefit a bit from FX on a quarter-over-quarter basis.
我們確實看到一些匯率(FX)帶來的好處,如同我們提到的;但這也反映了我們對這項業務的投資——擴增產能、在我們看到成長的地區增加布局——而本季是在槓桿化運用這些投資。因此這反映了我們所做的工作、我們能在全公司推動的生產力提升、對既有設施的利用,並且在季對季的基礎上,從匯率獲得一些助益。
Operator
Operator
The next question is from Elizabeth Anderson from Evercore.
下一個問題來自 Evercore 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Congrats on a nice quarter. Can you talk about any changes in your DSO strategy? I know you obviously, highlighted the DECA renewal in the quarter, but I just didn't know if there -- as we come out of COVID, anything to think about there in terms of how you're working with that group of customers?
恭喜本季表現不錯。你們能談談 DSO 策略是否有任何變化嗎?我知道你們在本季特別提到 DECA 的續約,但我不確定——隨著我們走出 COVID——在與這一類客戶群合作方式上,有沒有什麼需要留意的地方?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
No, Elizabeth, actually, we do, we can. We bring the entire Align digital platform together with iTero, the different -- some DSOs want to approach this thing from a comprehensive standpoint, some want noncomprehensive. So we just basically gear our digital platform and our product line based on what a DSO wants to do and what they want to accomplish, and not just in the U.S. but really all over the world.
沒有,Elizabeth,事實上我們可以(談)。我們把整個 Align 數位平台整合在一起,包括 iTero 等。不同的——有些 DSO 想以全方位的角度來推進,有些則偏好非全方位。所以我們基本上會依照 DSO 想怎麼做、想達成什麼目標,來配置我們的數位平台與產品線;而且不只是在美國,實際上是全球各地都是如此。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Got it. That's helpful. And then in terms of the new facility in Poland, should we think about the potential impact on the gross margin line to be similar to when you open the Ziyang facility? Or is there a different way that you -- that this one is different?
了解,這很有幫助。接著關於波蘭的新廠,對毛利率項目的潛在影響,我們是否應該把它想成類似你們當初開設資陽(Ziyang)廠時的情況?還是你們看待這座新廠的方式不同?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I think when we look at that, we'll leverage to ramp up that facility as fast as possible as a lot of volume can come through from EMEA. So I wouldn't look at that as a model for that. Remember what we did in China was a temporary facility to move to a greenfield, and this is a greenfield new facility to start with.
我想我們看待這件事時,會盡可能快速拉升(ramp up)該廠的產能,因為 EMEA 會有大量的量能可以導入。所以我不會把它當作那種模式來看。請記得,我們在中國做的是一個臨時性設施,之後要搬到一個綠地(greenfield)廠;而這次則是一開始就是一座全新的綠地新廠。
Operator
Operator
The next question is from Jon Block from Stifel.
下一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Joe, nice quarter. Two relatively quick ones. I guess to start, Joe, you called out EMEA and North America as the primary case volume, call it, upside drivers, not APAC. And just maybe if you could talk to APAC a little bit more. It was sort of first in COVID, and I think everyone was thinking first in, first out, but it seems like EMEA has been stronger. I mean, it was on a 2-year stack basis despite all the headline stuff that we hear in EMEA. Any details on APAC? Obviously, you've got a pretty big competitor in China. Any more granularity there would be very helpful. And then I've got a little bit of a tighter follow-up.
Joe,本季表現不錯。我有兩個相對快速的問題。首先,Joe,你提到 EMEA 與北美是病例量(case volume)上行的主要驅動因素,而不是 APAC。能否再多談一些 APAC?它算是最早受到 COVID 影響的地區,我想大家原本都以為會是「先進先出」,但看起來 EMEA 反而更強。我的意思是,即便我們在 EMEA 聽到很多新聞標題,EMEA 在兩年疊加(2-year stack)的基礎上仍然很強。APAC 有什麼細節可以分享嗎?尤其你們在中國有一個相當大的競爭對手。若能提供更細的拆解會很有幫助。然後我還有一個比較緊接的追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jon, first of all, I mean, EMEA was amazing in that way, but I wouldn't let it eclipse APAC, right? We feel really good about APAC across the board. China, obviously, being a big area, the sequential growth of China. When you look at fourth quarter versus first quarter, it's right in that 7%, 7.5% range like the entire business is. And then obviously, APAC is extremely diverse, but from Japan, ANZ, those key areas that we have in APAC, it's really strong growth.
Jon,首先,EMEA 的表現確實非常驚人,但我不會讓它掩蓋 APAC,對吧?我們對 APAC 整體都感到非常有信心。中國當然是一個很大的區域;中國的序列成長(sequential growth),你看第四季對第一季,大約就在 7% 到 7.5% 的區間,跟整體業務差不多。另外,APAC 非常多元,但從日本、澳紐(ANZ)等我們在 APAC 的關鍵市場來看,成長都非常強勁。
So I really feel great about APAC. It's just there's somewhat of an eclipse right now because EMEA was extremely strong. But you shouldn't let yourself think in any way that, that means APAC was weak in some way. We feel good about APAC as we go into the first quarter and the whole year.
所以我對 APAC 真的感到很振奮。只是因為 EMEA 特別強,所以目前看起來有點被掩蓋。但你不應該因此認為 APAC 在任何方面是疲弱的。我們對 APAC 在第一季以及全年展望都很有信心。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Yes, I guess, good problem to have. Second one is sort of a derivative of Nathan's question. But the biggest question I get from investors is this pull-forward of demand, right? In other words, is the 1Q '21 volume, call it, success, is that at the expense of future quarters? And it seems like your guidance suggests you're not too worried about that, Joe. But can you give us more detail here? Like why aren't you worried about any pull-forward? What are you hearing from sales reps? What are docs saying about sustaining the momentum throughout the year?
好的。是的,我想這算是個好問題。第二個問題有點延伸自 Nathan 的提問。但投資人問我最多的是需求是否被提前拉動(pull-forward),對吧?換句話說,2021 年第一季的量能表現(volume success),是否是以犧牲未來季度為代價?而你們的指引看起來顯示你並不太擔心這點,Joe。但你能否提供更多細節?例如你為什麼不擔心需求被提前透支?你從業務代表那邊聽到什麼?醫師對於全年維持動能有什麼看法?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, John. John, first of all, it's the breadth of this growth, right? It's not like it's a singular region like we just talked about with EMEA and APAC and how strong the Americas is. We're seeing great uptake in the GP side. We see terrific growth there, the orthodontic side. You see our team numbers are good and respectable. We're moving in the teen season.
是的,John。John,首先,是這項成長的廣度,對吧?它不像我們剛才談到的 EMEA 與 APAC 那樣是單一區域的表現,也不像美洲地區那麼強勁那樣單一來源。我們在 GP 端看到很好的採用率。我們在那裡、以及矯正端都看到極佳的成長。你也看到我們的團隊人數表現良好且可觀。我們正在進入青少年旺季。
So what we feel good about is just the breadth and depth of this business. It's not just leaning on 1 or 2 legs from a strategy standpoint, it really is well positioned going forward. We hear the same thing about demand pull-forward or whatever. We -- doctors aren't talking like that. Remember, the questions back in the third quarter, fourth quarter was backlog, right? How much of this was backlog that wasn't consummated in second quarter, early third quarter. And we got way past that. Obviously, we got into the fourth quarter, whatever.
所以我們感到樂觀的是,這項業務的廣度與深度。從策略角度來看,它不是只倚賴 1 或 2 條腿,而是未來確實具備良好的定位。我們也聽到同樣的說法,像是需求提前拉貨之類的。但我們——醫師並沒有那樣在談。記得第三季、第四季大家回問的問題是積壓訂單(backlog),對吧?有多少是第二季、第三季初沒有完成的積壓訂單。那一段我們早就過去了。顯然,我們進入了第四季,等等。
So I think we're just seeing a realization in the adult and the teen market of what digital orthodontics can do. And our company is very well positioned to take advantage of that when you look throughout the world. John, anything to add?
所以我認為,我們只是看到成人與青少年市場逐漸意識到數位矯正能做到什麼。當你放眼全球,我們公司非常有利於把握這個機會。John,有什麼要補充的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Okay.
好的。
Operator
Operator
The next question is from Kevin Caliendo from UBS.
下一個問題來自 UBS 的 Kevin Caliendo。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
I want to talk a little bit about how to think about seasonality with regards to teens. You typically -- you gear up the summer, it's a big teen season historically. Has there -- do you expect that again next year as sort of back-to-school might be a little more normal? And what -- how should we think about you gearing up for another incremental teen season? What might be different? Any expectations around incremental share for teens? I'd just love to hear the strategy.
我想談一下,關於青少年季節性該如何思考。通常——你們會在夏季做準備,歷史上夏季一直是青少年旺季。明年你們是否也預期會再次出現那樣的情況,因為返校季可能會更接近正常?另外——我們應該如何看待你們為下一個增量的青少年旺季做準備?會有哪些不同?對青少年增量市占有任何預期嗎?我很想聽聽策略。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I think we have a strategy really based on every region because the teen season is different by region from a calendar standpoint. And doctors apply our technology in different ways with teens. But let's just take U.S. and Canada for a second.
我想我們的策略其實是以各個區域為基礎,因為從日曆時間來看,各地的青少年旺季不同。而且醫師在青少年族群上使用我們技術的方式也不同。不過我們先以美國與加拿大為例。
Obviously, in the second quarter, beginning of third quarter, those are the really strong areas where you'll see our advertising program really kick in, in a big way. We talked about the Teen Awesomeness Centers that we put in place. That's with making sure that we have doctors that are really well-equipped to handle teens, and we direct the leads to that teams with confidence that they can be serviced properly.
顯然,在第二季、第三季初,那些是你會看到我們的廣告計畫大幅啟動、強力推進的時段。我們談過我們設立的 Teen Awesomeness Centers。那是為了確保我們有真正具備能力處理青少年病例的醫師,並且我們把潛在客戶名單導向那些團隊,讓我們有信心他們能被妥善服務。
Overseas, we understand what those timing are for the teens also, and we put those programs together, too. Honestly, Kevin, we have a great portfolio, right? And we can go across teens in a lot of different ways, all the way from 6 year olds, to really older teens when you get to 16 to 19 years old, and the tooth movements associated with those 2. So it's just having those doctors ready. It's having the communications with the teens and the moms to make sure they're aware of a digital orthodontic option, and they really ask for that as they go into the doctors. And that's a strategy we apply just in different ways and different seasons around the world, but it specifically applies to teens.
在海外,我們也了解青少年時點的安排,並同樣建立那些計畫。老實說,Kevin,我們有很棒的產品組合,對吧?我們可以用很多不同方式覆蓋青少年族群,從 6 歲的小朋友,一直到 16 到 19 歲的較大青少年,以及這兩者所涉及的牙齒移動類型。所以關鍵就是讓那些醫師準備好;也要與青少年與媽媽們溝通,確保他們知道有數位矯正的選項,並在就診時主動向醫師提出需求。這就是我們的策略,只是會因全球不同地區、不同季節而以不同方式執行,但它特別適用於青少年。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
That's helpful. And one -- just one follow-up on margins. The gross margin number was mentioned. You covered that already. Should we think about any of that flowing down to the operating margin? Or any sort of target for operating margins over the next couple of years? You've historically always looked to spend to grow, and it's always -- you've always been rewarded for it. There's no reason to change. But just thinking sort of where you are now, maybe if you do have a little bit of an uptick in the gross margin that you can let more of it flow through to the operating side. How do you think about that?
這很有幫助。還有——就毛利率再追問一點。你們提到了毛利率數字,你已經說過了。我們是否應該預期其中一部分會流向營業利益率?或者未來幾年營業利益率有沒有任何目標?你們過去一向是為了成長而投入支出,而且——也一直因此獲得回報,沒有理由改變。但只是想從你們現在的位置來看,如果毛利率稍微上升,是否能讓更多流到營運端?你們怎麼看?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I think when you look at it -- Kevin, this is John. I mean, we're looking to balance our growth opportunities with our margin. And in certain countries, you might be at different parts of that equation. But on balance, we're pleased with the gross margin. We've talked a lot about the investments, the productivity and other things that we see, and that continues. And it gives us a lot of flexibility to be able to invest.
我想從這個角度看——Kevin,我是 John。我的意思是,我們會在成長機會與利潤率之間尋求平衡。在某些國家,你可能處在那個方程式的不同位置。但整體而言,我們對毛利率感到滿意。我們談了很多投資、生產力以及我們看到的其他事項,而這些仍在持續。這也讓我們有很大的彈性可以進行投資。
But in a vastly underpenetrated market that we're in, making these investments to grow volume make a lot of sense to us. But we're always mindful of that balance between volume and margin.
但在我們所處這個滲透率仍然非常低的市場中,進行這些投資以提升量體,對我們而言很有意義。不過我們也一直留意量體與利潤率之間的平衡。
Operator
Operator
The next question is from Ravi Misra from Berenberg Capital Markets.
下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。
Ravi Misra - Analyst
Ravi Misra - Analyst
So just want to press a little bit more on kind of just some of the marketing opportunities that you're highlighting. And just curious, you have the ski team now, you're talking about the Golden State Warriors. I'm sure Draymond Green is not very happy about that. But just can you help us understand, like, what do you go after when you look at the marketing opportunity? Like in terms of the return that you're searching for the particular brands that you're aligning with? And then I have a follow-up after that.
我想再多追問一點你們強調的一些行銷機會。我很好奇,你們現在有滑雪隊,還提到金州勇士。我敢說 Draymond Green 對此可能不太開心。但你能否幫我們理解一下,你們在評估行銷機會時會追求什麼?例如你們在尋找的報酬、以及你們選擇對齊的特定品牌類型?然後我之後還有一個追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We do a lot of work on this, just figuring out what channels, what kind of return we get by channel, how much you put in social media, sports team, how much do you put in television. But overall, John and I expect a certain return, and we know what those returns are by region. We invest a dollar here, we know what we get back.
我們在這方面做了很多工作,就是去釐清哪些通路、各通路能帶來什麼樣的回報;社群媒體要投多少、運動隊伍要投多少、電視要投多少。但整體而言,John 和我會期待某個回報水準,而且我們也知道各地區的回報是多少。我們在這裡投 1 美元,我們知道能拿回什麼。
I don't necessarily want to convey exactly what those returns are but we make sure they're positive. And you've seen us increase our advertising pretty dramatically outside the United States. The response for that has been really good. And obviously, we use a lot of what we learned here in North America to apply that around the world.
我不一定想具體傳達那些回報到底是多少,但我們會確保它們是正向的。你也看到我們在美國以外的地區大幅提高廣告投入,而回應非常好。顯然,我們也把在北美學到的很多經驗應用到全球。
So Invisalign is an incredibly well-known brand, not just in North America, but all around the world. And being to leverage that and having that as kind of a common name around the world, it's very helpful for us in the sense of driving volumes, giving doctors confidence and patients confidence, too.
所以 Invisalign 是一個知名度極高的品牌,不只在北美,而是在全世界。能夠善用這點,並讓它在全球成為某種通用名稱,對我們在推動量體、提升醫師信心以及病患信心方面都非常有幫助。
So we really feel good about our investments. And obviously, we balance that well with increased salespeople, with technology investments, all the things you have to do when you run a business like this, but it is something that obviously gains a lot of attention and a lot of analysis from us.
所以我們對這些投資確實感到樂觀。當然,我們也會把它與增加業務人員、技術投資,以及經營這類業務所必須做的所有事情做良好平衡;但這確實是我們高度關注、也高度分析的一塊。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great. And then maybe just one on -- on the press release, something caught my eye around your kind of Ortho Summit Case Shoot-out where the highest vote was around kind of a Class II/Class III Invisalign case presentation. Historically, that's been something -- I think maybe -- that unless you're a bleeding edge KOL or doctor that you weren't doing. The fact that, that's kind of winning the kind of peer award now, does that suggest that you're getting deeper into these more complicated cases?
很好。那再問一個——在新聞稿上,有一點引起我注意:你們的 Ortho Summit Case Shoot-out 中,最高票似乎是某個 II 類/III 類 Invisalign 病例的展示。過去這一直是——我想——除非你是非常前沿的 KOL 或醫師,否則不太會做的事情。現在這樣的案例能贏得同儕獎項,是否意味著你們正在更深入處理這些更複雜的病例?
And just more specifically, do you feel that you have an edge versus your competitors in the space that allow you to do this? Or is this kind of a class effect that you think has to do with comfort and ease of use of the technology as a whole?
更具體地說,你們是否覺得自己相較於同業競爭者有優勢,能讓你們做到這點?還是你認為這是一種「類別效應」,更多是因為整體技術的舒適度與易用性提升所致?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Ravi, it's a good question. Look, remember, we have -- we've done, what, we said 10.2 million cases. And through those 10.2 million cases, we've learned a lot, and we learn more every day. And we run AI and machine learning across those cases. And that's how we just launched GA, as we understood and [defined] cases. We have some issues with posterior open bite and different clinical kind of issues that would bore you to death, but we understand based on millions of cases that we have done, which is the best way to move those teeth to ensure that they end up in the right positions with the right smile at -- obviously, you want to do this as quickly as you possibly can because patients don't want to be in treatment over 5 years.
是的,Ravi,這是個好問題。你看,記得我們已經——我們做了多少?我們說過 1,020 萬個案例。透過這 1,020 萬個案例,我們學到很多,而且每天都在學。我們也在這些案例上運行 AI 與機器學習。這也是我們如何推出 GA 的——因為我們理解並[定義]了案例。我們在後牙開咬(posterior open bite)以及不同的臨床問題上確實有一些議題,這些細節可能會讓你聽到睡著,但我們基於數百萬個已完成的案例,理解要用什麼最佳方式移動牙齒,確保最後能到達正確位置並呈現正確的笑容——而且顯然,你希望盡可能快地完成,因為病患不想治療拖到 5 年。
So I feel we have an incredible advantage. You look at SmartTrack, you look at how we initiate that with over 4 million lines of codes that we have in ClinCheck. You look at the accuracy of iTero in the sense of transferring information through over to our manufacturing facility in order to make this. It's so -- and I feel very confident about a 24-year first-mover advantage on what we've done.
所以我覺得我們擁有極大的優勢。你看看 SmartTrack,再看看我們如何透過 ClinCheck 裡超過 400 萬行程式碼來啟動它。你再看看 iTero 的精準度,能把資訊傳輸到我們的製造工廠來完成製作。這真的——而且我對我們在過去 24 年所建立的先行者優勢非常有信心。
Now obviously, there's competitors out there and competitors are coming up. But a lot of them have to crawl through the friction that we did in order to learn this. And a lot of the IP that we've put down that makes us unique in the sense of how we position ourselves in the marketplace. So back to what you started with, when you do these shoot-outs and all, it's really great to sit in the audience and look at the before and after photos. I mean it's amazing. When I first joined this business, I just said, I -- hard to believe that you can do this.
當然,市場上有競爭對手,而且競爭者也在崛起。但其中很多人必須像我們當初一樣,得先爬過那些摩擦成本,才能學會這些。而我們所佈建的大量智慧財產(IP),也讓我們在市場定位上具備獨特性。所以回到你一開始提到的,當你做這些對比測試之類的活動時,坐在觀眾席看那些前後對照照片真的很棒。我的意思是,太驚人了。我剛加入這個產業時,我就說,我——很難相信你竟然能做到這樣。
What's happening today is it's becoming more common. I mean you go all around the world. It was -- it's not 1 or 2 doctors doing this. There's hundreds, if not thousands, that are doing incredible kinds of cases. And so -- which I think that more and more, it just lends credibility to this product line. It can do what we say now 90% of all the cases that are out there. That's not just because it's plastic, right? It is the whole system from how we 3D print, what plastic we use, the algorithms we use, how we constantly tweak it by the information that we have, driving a brand like this, having the kind of training. We talked about 200,000 doctors that we've trained who've gone through these things. This takes time to do, it takes expertise. And doctors need that confidence in understanding. And we feel we can give it to them better than anyone.
而今天正在發生的是,這變得越來越普遍。我的意思是,你走遍全世界。這已經不是 1、2 位醫師在做這件事了。有數百位、甚至上千位醫師在做各種令人驚嘆的案例。所以——我認為這也讓這條產品線越來越具備可信度。它現在能做到我們所說的、涵蓋市面上 90% 的所有病例。這不只是因為它是塑膠材質,對吧?它是整個系統:從我們如何 3D 列印、使用什麼塑膠、使用什麼演算法、如何透過我們掌握的資訊持續微調;再到推動這樣的品牌、提供這種訓練。我們談到我們已經訓練了 20 萬名醫師,讓他們走過這些流程。這需要時間、需要專業。而醫師需要那份理解後的信心。我們覺得我們能比任何人更好地提供給他們。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And that technology is brought about by investments, and we'll invest over $250 million this year alone in R&D to improve our systems and Invisalign for our customers. And that's an advantage. It's an advantage, like Joe said, over a period of time, but we're continuing to invest to make things better and better for our customers.
而這些技術是透過投資帶來的;僅今年一年,我們就會在研發(R&D)上投資超過 2.5 億美元,以改善我們的系統以及為客戶提升 Invisalign。這就是一個優勢。這是一個優勢——就像 Joe 說的——是長期累積的,但我們也會持續投資,讓一切對客戶而言變得越來越好。
Operator
Operator
The next question is from Richard Newitter from SVB Leerink.
下一個問題來自 SVB Leerink 的 Richard Newitter。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
This is Jaime on for Rich. Just one question for me. Appreciating that you guys are obviously focused on driving higher ortho teen utilization, overall GP adoption at the same time. I'm just curious, in your view, which of the 2 is likely to be the bigger make-or-break driver of growth over the near to intermediate term?
我是 Jaime,代 Rich 提問。我這邊只有一個問題。理解你們顯然同時專注於提升青少年矯正(ortho teen)的使用率,以及整體 GP(一般牙醫)採用率。我只是好奇,以你們的觀點,在短期到中期之間,這兩者之中哪一個更可能成為成長的關鍵決定因素(make-or-break driver)?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
You know, it just sounds like a terrible answer to you, but they're both. Really, we talk about 500 million patients out there that could use Invisalign treatment. We know that of the 15 million orthodontic cases, roughly 75% to 80% are teens -- I mean all those -- they're both huge opportunities. And there's not a difference from a technology standpoint or how you apply that technology to either of those that would make one easier to do or more beneficial than another. So honestly, both of those are great reservoirs of growth for us.
你知道,這聽起來可能是個很糟的答案,但兩者都是。真的,我們談到市場上有 5 億名患者可能需要 Invisalign 治療。我們也知道,在 1,500 萬個齒顎矯正病例中,大約 75% 到 80% 是青少年——我的意思是,這些——兩者都是巨大的機會。而從技術角度或技術應用方式來看,並沒有什麼差異會讓其中一個更容易做或比另一個更有利。所以老實說,這兩者對我們而言都是很棒的成長蓄水池。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
Got it. Okay. And then just...
了解。好。那接著……
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Go ahead, Jaime.
你說吧,Jaime。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
One last one for me, just on the DSO. Kind of the business model and strategy that you guys have for entrenching iTero systems in DSOs across all practices, kind of how do you approach that? And when you do see DSOs where the large majority of their practices have adopt the iTero scanner, what's the sort of pickup that you guys see in terms of utilization?
我最後一個問題,關於 DSO。你們在 DSO 旗下所有診所中深化(entrenching)iTero 系統的商業模式與策略大概是什麼?你們是如何切入的?另外,當你們看到某些 DSO 旗下絕大多數診所都採用 iTero 掃描儀時,你們在使用量(utilization)方面通常會看到怎樣的提升幅度?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, we -- where you use iTero scanners, you train the doctors properly, you have the right products in a GP channel like iGo and different products like that. We get terrific uptake. I mean, you can't measure it the way you do share a chair at the orthodontic office. But we get -- our DSO business is significant now. It's meaningful that way. And it's one where that digital platform strategy, as you kind of outlined in your question, is what we employ. But again, we employ it in different ways, depending on how a DSO really wants to engage with us.
嗯,我們——在使用 iTero 掃描儀的地方,如果你把醫師訓練到位,並且在 GP 通路提供像 iGo 以及其他不同產品這樣合適的產品組合,我們會看到非常好的導入與成長(uptake)。我的意思是,你無法像在矯正診所那樣用「每張椅位的市占」去衡量。但我們——我們的 DSO 業務現在已經相當可觀,從這個角度來看是很有意義的。而你在問題中提到的那種數位平台策略,正是我們所採用的。不過同樣地,我們會用不同方式來執行,取決於 DSO 想要如何與我們合作互動。
Operator
Operator
Next question is from Jeff Johnson from Baird.
下一個問題來自 Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
John, I want to go back. You mentioned the $250 million in R&D. And I think the number we've discussed over the last, I don't know, probably somewhere in the last 6 or 9 months or so, it's like $500 million total of what you guys spend, not only on R&D, but channel support, advertising, social media, all that stuff. And on our mind, that's one of your bigger barriers to entry, even probably more so than some of the IP and what have you.
John,我想回到你剛提到的 2.5 億美元研發。我想我們在過去——我不知道——大概過去 6 到 9 個月左右討論過的數字是,你們總共花大約 5 億美元,不只是研發,還包括通路支援、廣告、社群媒體等等。在我們看來,這是你們較大的進入門檻之一,甚至可能比某些 IP 或其他因素更重要。
But it sounds like with some of the stuff, you're taking up EMEA, you're taking up APAC advertising, more and more sports teams and things like that. Is that $500 million number a dated number at this point? Is that barrier to entry and that spend even going well above that number in the near to intermediate term?
但聽起來,隨著你們在一些事情上加碼——你們加大 EMEA、加大 APAC 的廣告投放,越來越多的運動隊伍合作之類——那個 5 億美元的數字現在是否已經過時?在短期到中期,這個進入門檻與支出是否會明顯高於那個數字?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
You will see that. That's a good question, Jeff. We talked about that at our last Investor Day, about the $500 million combined kind of the marketing go-to-market plus the R&D. And what you'll see is as in success. And we've talked about a lot, as you know, where we see returns, where we see volume, where we see profitability, we're going to continue to make those investments. So as we go through this year, that number will most likely go up as we find success in these investments and find that right return.
你會看到那樣的情況。這是個好問題,Jeff。我們在上一次投資人日談過那個 5 億美元,指的是「行銷/市場推進(go-to-market)」加上研發的合計。你會看到的是,隨著成功——而且我們也談過很多次,如你所知——在我們看到回報、看到量、看到獲利的地方,我們會持續進行這些投資。所以在今年的推進過程中,隨著我們在這些投資上看到成功並找到合適的回報,那個數字很可能會上升。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Yes. Fair enough. And Joe, I'd be interested. I mean, we saw COVID case counts and restrictions even in the 1Q in some of the markets you called out in EMEA as being so strong, U.K., France. I'm sure some others, you called out other areas. Obviously. India that we're all watching closely, but a lot of other markets as well that are still dealing with COVID case counts and heightened risks there.
是的,可以理解。那 Joe,我也想請教。我們看到即使在某些你提到 EMEA 表現很強的市場——英國、法國——在第一季仍有 COVID 病例數與限制。我相信還有其他一些市場,你也點名了其他地區。當然,印度是大家都在密切關注的,但也有很多其他市場仍在面對 COVID 病例數與更高的風險。
Does that even matter to case shipments to Invisalign at this point? I guess what I'm trying to figure out is, is that stuff holding back some volumes that could come through next year? Are we all just with COVID fatigue still comfortable going in and getting Clear Aligner cases even in those markets? So is COVID a risk factor, I guess, that you've had to build in some caution in the guidance for in some of those markets? Or are cases just as strong in those markets as they are in markets where maybe COVID is a little more under control?
在這個時間點,這些因素對 Invisalign 的病例出貨(case shipments)還有影響嗎?我想弄清楚的是:這些狀況是否正在壓抑一些量,可能會在明年釋放出來?或者大家在「COVID 疲乏」之下,即使在那些市場也仍然願意去診所做透明牙套病例?所以我想問的是,COVID 是否仍是一個風險因子——你們在對某些市場的財測指引(guidance)中是否必須納入一些保守考量?還是說,那些市場的病例表現其實跟 COVID 相對受控的市場一樣強?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Jeff, it's a good question. It's just what we've seen. There's one definitive. If offices are shut down and patients aren't allowed to go to offices, we saw that. That happened in the second quarter, it happened all around the world. And then the term lockdown is used very loosely all around the world, what's a lockdown and what isn't. The situations like in India right now are a disaster, obviously, and people are very cautious. But the rest of the way around the world, what we see is it looks like communities and people have been able to manage this, okay? Is there any kind of a backlog of patients not going into dental offices because of that? I think in certain countries around the world, there is, but we can't really quantify that right now. And again, the breadth and depth of our demand pattern gives us confidence that we think we can predict around it.
是的,Jeff,這是個好問題。我們看到的情況是,有一件事很明確:如果診所關閉、患者不被允許去診所,我們就會看到影響。第二季就發生過,而且是全球各地都發生過。然後「封城(lockdown)」這個詞在世界各地被用得很寬鬆,什麼算封城、什麼不算,各地定義不同。像印度現在的情況顯然是一場災難,人們也非常謹慎。但在世界其他地方,我們看到的是,社區與民眾似乎已經能夠把這件事管理得還可以。是否存在某種因為這個原因而沒有去牙科診所、所累積的患者待處理量(backlog)?我認為在世界某些國家是有的,但我們目前無法真正量化。而且再說一次,我們需求型態的廣度與深度讓我們有信心,認為我們可以在這些因素周邊做出預測。
Operator
Operator
The next question is from Erin Wright from Crédit Suisse.
下一個問題來自瑞士信貸(Crédit Suisse)的 Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Great. Can you speak a little bit about what you're doing differently in terms of promotions or other initiatives around iTero that's really resonating with customers maybe differently now? And where is the traction mostly tied to, on the ortho or GP channel? And do you anticipate any lumpiness quarter-to-quarter across that business?
很好。能否談談你們在 iTero 相關的促銷或其他推動措施上,現在有哪些不同做法,特別是哪些做法更能引起客戶共鳴?目前的動能主要來自矯正(ortho)通路還是一般牙科(GP)通路?另外,你是否預期這項業務在各季之間會有一些不均勻(lumpiness)的波動?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Well, iTero's been great for us, right? You have a good services business there. We announced the Plus series iTero, which is -- Erin, it's a breakthrough. I mean, it sounds like it's a derivative as far as incremental but it is really a strong platform. We talk about the artificial intelligence we've been able to embed in that machine. We see doctors, both on the GP side and the orthodontic side, really excited about it. This is not a promotional discussion in a sense of when you ask your question about how to promote it. There's nothing tricky there. What we do is we have a broad number of products. You have the NIRI product plus, which is the very high end of the product line. Then you have a flex system, which I mentioned in my opening, which is basically a wand itself and it's used with the -- a normal kind of a computer that's adapted to that. And it helps to get flexibility in the sense of what a customer wants to use or a doctor wants to use on both ends.
是的。嗯,iTero 對我們來說一直很棒,對吧?那裡有一個很好的服務型業務。我們宣布了 iTero Plus 系列——Erin,這是一項突破。我的意思是,聽起來好像只是漸進式的衍生改款,但它其實是一個非常強大的平台。我們談到我們能夠嵌入到這台設備中的人工智慧。我們看到醫師,不論是 GP 端或矯正端,都對此非常興奮。這並不是一個促銷層面的討論,也就是說,當你問到要如何推廣它時,這裡沒有什麼花招。我們所做的是,我們有相當廣泛的產品組合。你有 NIRI product plus,這是產品線中非常高階的產品。然後你還有一個彈性系統,我在開場時提到過,基本上它是一支掃描棒(wand),搭配——一台經過調整的普通電腦來使用。它能在客戶或醫師在兩端(不同需求)想要使用的方式上,提供彈性。
So I feel it's like how we take this to market, the different products that we have and the different way that we segment that is -- and then, obviously, if you want to do Invisalign, this is the front end, the key end of our digital platform and that's very attractive to both GPs and orthos that really want to do Invisalign. They know that iTero is critical for that.
所以我覺得這更像是我們如何把這些產品推向市場:我們有哪些不同的產品,以及我們如何用不同方式去做區隔——然後,顯然,如果你想做 Invisalign,這就是我們數位平台的前端、關鍵端,對於真正想做 Invisalign 的 GP 與矯正醫師都非常有吸引力。他們知道 iTero 對此至關重要。
Operator
Operator
The next question is from Brandon Couillard from Jefferies.
下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
John, maybe just a 2-part question around guidance. The operating margin outlook would suggest your margins kind of moderate a bit over the balance of the year from 1Q levels. Can you sort of elaborate on your expectations for gross margins for the balance of the year? And then what should we -- how should we think about the trend of ASPs over the next few quarters? I'd just leave it there.
John,我有一個關於財測(guidance)的兩部分問題。營業利益率的展望似乎暗示你們今年剩餘期間的利潤率會從第一季的水準稍微回落一些。你能否說明一下你們對今年剩餘期間毛利率的預期?另外,我們應該——我們應該如何看待未來幾季 ASP(平均售價)的趨勢?我就先問到這裡。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Brandon, when we look at -- we're pleased with our gross margin and margins that we had in the first quarter. A lot of things came together on that. When we look at the investments and the growth opportunities we have, we're not giving specific guidance around our gross margin. What you can see as it translates to op margins, it's a reflection of the growth opportunities we have, the investment opportunities that we have to be able to invest and grow in this business. And we can update as we go forward based on what we see.
是的。Brandon,當我們回頭看——我們對第一季的毛利率以及利潤率表現感到滿意。很多因素在那一季都配合得很好。當我們看我們的投資與成長機會時,我們不會就毛利率提供具體指引。你可以從它如何反映到營業利益率來看:這反映了我們所擁有的成長機會、我們所擁有的投資機會,使我們能夠投資並推動這項業務成長。我們也可以在往後根據我們看到的情況持續更新。
Your other part of the question regarding kind of ASPs and so on. When you look at -- we have a breakout, and we show that on a regular basis between comprehensive and noncomprehensive. We don't expect any major fluctuation across our ASPs. The only thing that comes up, and we saw it in this quarter a bit was with currency changes. But in terms of the promotions and how we go about the business and how we're trying to drive growth, there's nothing out of the ordinary that would impact ASPs.
你問題的另一部分是關於 ASP 等等。當你看——我們有做拆分,並且定期揭露 comprehensive 與 noncomprehensive 之間的差異。我們不預期 ASP 會出現任何重大波動。唯一會出現的因素——而我們在本季也稍微看到——是匯率變動。但就促銷以及我們如何經營業務、如何推動成長而言,沒有任何異常情況會影響 ASP。
Operator
Operator
The next question is from John Kreger from William Blair.
下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
I just wanted to follow-up on Jeff's question a bit. So if you move beyond office closures, as you look at certain regions of the world becoming hot spots and then that fading, does that impact demand levels that you're seeing?
我想稍微追問一下 Jeff 的問題。所以如果我們先不談診所關閉,當你看到全球某些地區成為疫情熱點、之後又逐漸消退時,這是否會影響你們所看到的需求水準?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
It's not a great answer for us, John, it's yes and no, okay? Depending on the severity and where it is, I can say yes. For the most part, we say no. And that's after the second quarter when, again, the definitive piece, if you shut offices down and you won't let patients in there, we're going to have an issue. But actually, after the second quarter, early third quarter, we've been dealing with lockdowns that are basically lockdowns of time frame, lockdowns of where people can travel, but not specific lockdowns of doctor offices. If the market stays away from that, we feel we're pretty good.
John,這對我們來說不是一個很好的答案,但答案是「是也不是」,好嗎?取決於嚴重程度以及發生在哪裡,我可以說會(有影響)。但大多數情況下,我們會說不會。這是在第二季之後——再次強調,最關鍵的一點是:如果你把診所關掉、不讓病人進去,那我們就會有問題。但實際上,在第二季之後、第三季初以來,我們面對的封鎖基本上是有時間範圍的封鎖、是人們可以去哪裡旅行的限制,而不是針對牙醫診所的特定封鎖。如果市場能避免走回那種情況,我們覺得我們就相當不錯。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thanks, John. Operator, we'll take one more question.
謝謝,John。接線員,我們再接最後一個問題。
Operator
Operator
The next question is from Michael Ryskin of Bank of America.
下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
I'll just ask a quick one. Sort of want to expand a little bit on the ASP question that was just asked. I'm just wondering, you cited a little bit in your prepared remarks in terms of promotional things like that, discounts. Are you referring specifically to the Advantage program? And if you could talk about how some of the orthos and GPs are falling in with those tiers. Have you seen any movement over the last couple of quarters where people are falling more into the platinum and the diamond grouping there? Kind of also backing into sort of the numbers on utilization between ortho, I've seen some really nice numbers the last couple of quarters. Is that indicative of that, a higher portion of orthos and GPs falling at those higher tiers and therefore, walking in those -- the higher promotional discounts?
我快速問一個。我想把剛才的 ASP 問題再延伸一下。我在想,你在事先準備的發言中提到了一些促銷之類的事情、折扣。我想確認一下,你指的是特別是 Advantage 計畫嗎?如果可以的話,也請談談矯正醫師與 GP 在那些等級(tiers)中的分布情況。過去幾季你們是否看到有人更多地落在白金(platinum)與鑽石(diamond)那一組?另外,從某種角度回推矯正端的使用量(utilization)數字——我看到過去幾季有一些非常不錯的數字——這是否意味著有更高比例的矯正醫師與 GP 落在那些較高等級,因此也享有——較高的促銷折扣?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Certainly, that is an impact. When you have -- as doctors grow through the tiers, they become more proficient. They had taken on more cases, whether they're on the ortho side or the GP side, we see them work their way through tiers. They do more cases, then we get that volume benefit. And then they'll see those discounts there.
是的。當然,那確實會造成影響。當你有——隨著醫師在等級中往上成長,他們會變得更熟練。他們承接了更多病例,不論是在矯正端或 GP 端,我們都看到他們逐步往上升等。他們做更多病例,然後我們就能獲得那個量的效益。接著他們也會看到那些折扣。
We've had those programs in place. Those programs really help drive utilization and really talk to the utilization growth that you noted there. So those are programs that we've had. They're there to drive utilization, and it's something that we've used in our business and expect to continue to use.
我們一直都有這些計畫。這些計畫確實有助於推動使用量,也呼應你提到的使用量成長。所以這些是我們既有的計畫。它們的目的就是推動使用量,這也是我們在業務中一直使用、並且預期會持續使用的做法。
Operator
Operator
This concludes the question-and-answer session. I'd like to turn the call back over to Shirley Stacy for closing remarks.
問答環節到此結束。我想把電話交回給 Shirley Stacy 作結語。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, thank you, everyone, for joining us today. We appreciate your time. We look forward to seeing you or speaking with you at upcoming financial conferences and industry meetings and events. If you have any follow-up questions, please contact our Investor Relations department. Have a great day.
好的,謝謝各位今天加入我們。我們感謝各位撥冗。我們期待在接下來的財務會議與產業會議及活動中見到各位或與各位交流。如果你們有任何後續問題,請聯絡我們的投資人關係部門。祝各位有美好的一天。
Operator
Operator
This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.
今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。